

TITLE PAGE

Title:

Immediate effect of osteopathic techniques on human resting muscle tone in healthy subjects using myotonometry: A factorial randomized trial

Author information:

Lucas Bohlen, MSc (lbohlen@osteopathie-schule.de) ^{1*}

Jonah Schwarze, MSc (jschwarze@osteopathie-schule.de) ¹

Jannik Richter, MSc (jannikrichter@gmx.net) ^{2,3}

Bernadette Gietl, MSc (bernadette.gietl@gmx.de) ^{2,3}

Christian Lazarov, BSc (c.lazarov@gmx.de) ^{2,3}

Anna Kopyakova, MSc (anna.kopyakova@gmail.com) ⁴

Andreas Brandl, MSc (brandl.andreas@stud.diploma.de) ⁵

Dr. Dr. Tobias Schmidt, MSc (to.schmidt@asklepios.com) ¹

Affiliations:

¹ Osteopathic Research Institute, Osteopathie Schule Deutschland, Hamburg, Germany.

² Osteopathie Schule Deutschland, Hamburg, Germany.

³ Dresden International University, Dresden, Germany.

⁴ Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, Netherlands.

⁵ DIPLOMA Hochschule, Bad Sooden-Allendorf, Germany.

***Corresponding author:**

Name: Lucas Bohlen; **Postal code:** Mexikoring 19, 22297 Hamburg, Germany; **E-Mail:**

lbohlen@osteopathie-schule.de.

26

ABSTRACT**Background:**

Musculoskeletal disorders (MSDs) are highly prevalent, burdensome, and putatively associated with an altered human resting muscle tone (HRMT). Osteopathic manipulative treatment (OMT) is commonly and effectively applied to treat MSDs and reputedly influences the HRMT. Arguably, OMT may modulate alterations in HRMT underlying MSDs. However, there is sparse evidence even for the effect of OMT on HRMT in healthy subjects.

Methods:

A 3x3 factorial randomised trial was performed to investigate the immediate-term effect of myofascial release (MRT), muscle energy (MET), and soft tissue techniques (STT) on the HRMT of the corrugator supercilii (CS), superficial masseter (SM), and upper trapezius muscles (UT) in healthy subjects in Hamburg, Germany. Participants were randomised into three groups (1:1:1 allocation ratio) receiving treatment, according to different muscle-technique pairings, over the course of three sessions with one-week washout periods. Primarily, we assessed the effect of osteopathic techniques on muscle tone (F), biomechanical (S, D), and viscoelastic properties (R, C) from baseline to follow-up (main effect) and tested if specific muscle-technique pairs modulate the effect pre- to post-intervention (interaction effect) using the MyotonPRO (at rest). Data were analysed using descriptive (mean, standard deviation, quantiles, and simple effect) and inductive statistics (Bayesian ANOVA).

Results:

59 healthy participants were randomised into three groups and two subjects dropped out from one group (n=20; n=20; n=19 and n=17, respectively). The CS produced frequent measurement errors and was excluded from analysis. The main effect

51 changed significantly for F (-0.163 [0.060]; $p=0.008$), S (-3.060 [1.563]; $p=0.048$), R
52 (0.594 [0.141]; $p<0.001$), and C (0.038 [0.017]; $p=0.028$) but not for D (0.011 [0.017];
53 $p=0.527$). The interaction effect did not change significantly ($p>0.05$). No adverse
54 events were reported.

55 **Conclusion:**

56 OMT modified the HRMT in healthy subjects which may inform future research on
57 MSDs. In detail, MRT, MET, and STT reduced the muscle tone (F), decreased
58 biomechanical (S not D), and increased viscoelastic properties (R and C) of the SM
59 and UT (CS was not measurable) at immediate term. However, the effect on HRMT
60 was not modulated by muscle-technique interaction.

61 **Trial registration:**

62 German Clinical Trial Register (DRKS00020393).

63 **Key words:**

64 Osteopathy; Osteopathic techniques; Osteopathic manipulative treatment; Muscle
65 tone; Human resting muscle tone; Biomechanical muscle properties; Viscoelastic
66 muscle properties; Musculoskeletal disorders, MyotonPRO.

67

INTRODUCTION

Background:

69 Globally, musculoskeletal disorders (MSDs) accounted for ~1.3 billion prevalent and
70 ~334.7 million incident cases in 2017 [1]. Notably, most of the prevalence and
71 incidence is attributable to gout, rheumatoid arthritis, osteoarthritis, neck pain
72 (NP), and low back pain (LBP) [2, 3]. In 2017, MSDs were the main contributor to
73 global disability and LBP was the leading cause of disability since 1990 [4]. Similarly,
74 the global costs of MSDs due to health expenditure and production loss are reported
75 to be immense [5]. However, these high health costs mismatch with low research
76 investments [6] and policy responses are thus required to close the gap [7]. Hence,
77 MSDs are highly prevalent, burdensome, and costly.

78

79 In primary care, musculoskeletal pain should be managed according to current best
80 evidence and practice recommendations, which report beneficial effects of manual
81 therapy but merely endorse adjunct treatment [8] due to limited high-quality
82 evidence [9]. Still, patients with MSDs like LBP seem to prefer non-surgical [10] and
83 non-pharmacological interventions [11] of whom manual therapy provides the best
84 evidence for immediate-term reduction of pain and disability in acute and subacute
85 non-specific LBP [12]. Hence, patients with MSDs may consult an osteopath in
86 primary care - depending on varying country regulations and professional
87 recognitions across the world [9, 13]. Osteopathic practice should, in turn, adhere
88 to established treatment recommendations, which it arguably does (**Box 1**).

89 **Box 1 | Osteopathic practice and musculoskeletal care recommendations**

90 A recent systematic review of high-quality clinical practice guidelines put forward 11 recommendations for best practice care
91 in musculoskeletal pain conditions emphasising: (1) patient centred care, (2) screening for red flags, (3) assessing of
92 psychosocial factors, (4) using imaging only selectively, (5) carrying out a physical examination, (6) recording the patients'
93 progress, (7) providing patient education, (8) fostering physical activity and exercise, (9) applying manual therapy in
94 multimodal care setting, (10) offering non-surgical care first, and (11) keeping patients working [8]. Arguably, osteopathy
95 fulfils most of the criteria by: (1) being a patient-centered, or even person-centered, care approach [14, 15], (2) using an
96 initial biomedical screening for red flags/serious underlying pathology [16], (3) assessing, and putatively influencing,
97 psychosocial factors [17, 18], (4) using imaging only occasionally and mostly by referral [19, 20], (5) always carrying out
98 physical examinations [21], (6) keeping patient records to monitor progress [20], (7) providing patient education [13, 22], (8)
99 giving advice on physical activity and exercise [13, 23], (9) using manual therapy and recognizing the need for multimodal
100 care [24], (10) offering non-surgical care, sometimes before and/or after surgery [25], and (11) aiming to promote the patient's
101 return to work [26, 27].

102

103 Osteopathy is a person-centered approach to healthcare that aims to enhance,
104 restore, or maintain the patient's (self-regulation of) structure, function, and well-
105 being [13, 21]. Therefore, osteopaths employ both manual (e.g., touch, palpation,
106 and manipulation) and patient management approaches (e.g., patient education,
107 psychological support, lifestyle advice, and self-management solutions) [28]. In
108 practice, palpatory findings are interpreted according to an osteopathic clinical
109 reasoning process [16] that considers biopsychosocial perspectives [29] and
110 osteopathic models of care [30]. These findings are then treated using osteopathic
111 manipulative treatment (OMT) [31], which encompasses different approaches (e.g.,
112 direct, indirect, and combined methods) and techniques (e.g., myofascial release,
113 muscle energy, and soft tissue techniques) [32] (**Box 2**).

114

115 **Box 2 | Overview about myofascial release, muscle energy, and soft tissue techniques**

116 Herein, we provide an overview about the definition, mechanisms, and effects of three manual techniques frequently used in
117 the osteopathic field: (1) **Myofascial release technique (MRT)**: (1.1) **Definition**: MRT uses pressure and stretch with low load
118 and long duration (which are adjusted based on palpatory feedback) to release myofascial tissues [33, 34]; (1.2) **Mechanisms**:
119 MRT is underlined by mechanisms that are not fully understood [35, 36], however, it seems to induce fibroblasts to upregulate

120 the production of anti-inflammatory cytokines and growth factors [37]; and **(1.3) Effects:** MRT shows mixed results for treating
121 painful (often chronic) musculoskeletal conditions [33, 34, 38] as it reduces pain and improves function in patients with cLBP
122 [39] while reducing disability, but not pain, in patients with LBP [40]; **(2) Muscle energy technique (MET):** **(2.1) Definition:**
123 MET involves instructing the patient to voluntarily contract muscles into a controlled direction against the therapist counter-
124 pressure [41]; **(2.2) Mechanisms:** MET has unclear mechanisms of action with some speculating changes in proprioception,
125 inflammation, and fluid circulation [42] and others emphasising post-isometric relaxation and reciprocal inhibition [43]; and
126 **(2.3) Effects:** MET is effective in improving pain, disability, and range of motion in symptomatic and asymptomatic subjects,
127 specifically in chronic MSDs like cLBP [43]; and **(3) Soft tissue technique (STT):** **(3.1) Definition:** STT applies stretch, traction
128 and/or deep pressure to soft tissues [32]; herein, we used repeated, slow, and deep pressure gliding strokes applied with the
129 thumb alongside the muscle fibres, which is a STT that is similar to muscle stripping massage [44-46]; **(3.2) Mechanisms:** STT
130 (or therapeutic massage, respectively) might work through mechanotransduction [47, 48] albeit other biomechanical,
131 physiological, neurological, and psychological mechanisms are not to be disregarded [49, 50]; and **(3.3) Effects:** STT (or
132 massage therapy, respectively) benefits patients with LBP [51, 52] and improves pain and function in patients with cLBP in
133 the short-term [50].

134

135 OMT is primarily, but not exclusively, applied to treat musculoskeletal pain
136 conditions like back pain [53] employing, among others, spinal [54] and visceral
137 manipulations [55]. Current evidence suggests that osteopathic treatment may
138 improve pain and function in patients with spinal complaints [56], including chronic
139 NP [57] and acute and chronic non-specific LBP [58-60] even during pregnancy and
140 postpartum [61]. OMT was recommended for patients with LBP [31], indicated to
141 benefit medical care [62], proposed to be included within chronic pain management
142 guidelines [63], and even reported to be dominant and cost-effective compared to
143 usual care in the management of LBP and NP, respectively [64]. Still, the current
144 body of evidence lacks robustness due to methodological shortfalls and
145 counterevidence is available as well [65-67].

146

147 Taken together, MSDs and OMT are complex health conditions and interventions,
148 respectively. Both are underlined by mechanisms that are poorly understood [30,
149 68] and associated with various biological, psychological, and social factors [69, 70].

150 However, of particular interest is that both MSDs [71, 72] and OMT [73-76] are
151 reputed to be associated with changes in muscle tone. On the one hand, alterations
152 in lumbar myofascial tone and stiffness seem to contribute to the development of
153 LBP [77] and may be linked to underlying pathologies and symptoms [71, 72]. On the
154 other hand, manual osteopathic treatment is assumed to alter muscle tone and
155 stiffness [73-76], for example, of paraspinal muscles in patients with LBP [71].
156 Therefore, we hypothesise that a putative mechanism of action underpinning the
157 treatment of MSDs with OMT might be the modulation of muscle tone.

158

159 In general, muscle tone relates to the resting tension of the tissue in response to
160 stretch. A differentiation can be drawn between: (1) active muscle tone: relating to
161 the electrical activity within muscle cells; and (2) passive muscle tone: relating to
162 the intrinsic biomechanical and viscoelastic properties of the muscle [72, 78]. The
163 human resting muscle tone (HRMT) broadens the concept of passive muscle tone to
164 include other connective tissues thereby accounting for the passive/resting tension
165 of all continuous myofascial tissues involved in the body's biotensegrity system [79].
166 It was suggested that the HRMT is generated by 'slowly cycling cross-bridges'
167 between myosin heads and actin filaments [77, 79, 80]; however, other molecular
168 and cellular mechanisms have been put forward and further research is required to
169 conclusively determine the mechanisms underlying the HRMT [81].

170

171 Notably, the HRMT seems to be particularly relevant to clinical and manual practice
172 [79]. Still, previous studies assessing the presumed effect of osteopathy on muscle
173 tone used palpation and electromyography (EMG) as measures [82-84]. However,
174 manual palpation is reported to be unreliable [85-92] and EMG is not informative of

175 the HRMT [79]. Nonetheless, it appears imperative to detect these changes in
176 research and practice. Thus, the use of a myotonometer was emphasized to reduce
177 the subjectivity in determining the HRMT [71, 81]. An objective and reliable
178 myotonometer is the MyotonPRO which induces oscillations in the muscle fibres as a
179 means of quantifying biomechanical and viscoelastic muscle properties [71, 72, 93].

180 Objectives:

181 Hence, in this study, we assessed the effect of osteopathic modalities on the HRMT
182 in healthy subjects using the MyotonPRO to inform future research on MSDs. In
183 detail, three osteopathic techniques with different characteristics (myofascial
184 release technique [MRT], muscle energy technique [MET], and soft tissue technique
185 [STT]) were used to influence the HRMT of three muscles with different sizes and
186 thicknesses (corrugator supercilii muscle [CS], superficial masseter muscle [SM], and
187 upper trapezius muscle [UT]) (**Box 3**). Primarily, we evaluated whether osteopathic
188 techniques influence the tone (F), biomechanical (S and D) and viscoelastic (R and
189 C) properties of these muscles in all groups from baseline to follow-up using the
190 MyotonPRO (main effect). Secondly, we investigated if muscle-technique pairs
191 modulate the putative effect in each group from pre- to post-intervention using the
192 MyotonPRO (interaction effect). For the primary objective, we hypothesized that
193 osteopathic techniques reduce the muscle tone (F) and biomechanical properties (S
194 and D) and increase the viscoelastic properties (R and C). For the secondary
195 objective, we hypothesized that the predicted changes in muscle properties of the
196 CS, SM, and UT are preferentially achieved through MRT, MET, and STT, respectively.

197 **Box 3 | Muscle characteristics**

198 The CS, SM, and UT were selected for this study due to their apparent differences in size and thickness. However, the
199 availability of data on both size and thickness were scattered and the values given below are to be interpreted with caution.

200 In detail, it has been reported that the relaxed muscle thickness of the (1) CS ranges between 5 and 6 mm [94]; (2) SM ranges
201 between 9 and 15 mm (notably, values account for the combined thickness of the superficial and deep part of the masseter
202 muscle and are thus exaggerated) [95], and (3) UT ranges between 11 and 12 mm [96]. No data was available on the surface
203 size of these muscles. Hence, we calculated an approximate surface size based on data reporting the length and width of
204 these muscles (which is imprecise as it does not account for factors like muscle shape). In detail, we calculated a surface size
205 for the (1) CS of $\sim 3.69 \text{ cm}^2$ (length: 29.24 mm; width: 12.62 mm) [97]; (2) SM of $\sim 24.40 \text{ cm}^2$ (length: 6.32 cm; width: 3.86 cm)
206 [98]; and (3) UT of $\sim 540 \text{ cm}^2$ (length: 45 cm; width: 12 cm) (notably, this data is based on a myocutaneous trapezius flap and
207 likely imprecise) [99].

208

209

METHODS

210 **Trial design:**

211 This single-blinded 3x3 factorial randomised trial was conducted in Hamburg,
212 Germany. No changes to the methods were made after trial commencement. The
213 study is largely reported according to the CONSORT statement [100, 101] since there
214 are currently no specific guidelines available for randomised trials using a factorial
215 design [102]. This study has obtained informed consent from participants, was
216 carried out in accordance with the Declaration of Helsinki [103] and was approved
217 by the ethics committee of the Osteopathic Research Institute (Nr. 020-01). The
218 study was prospectively registered within the German Clinical Trial Register
219 (DRKS00020393).

220 **Trial procedure:**

221 Participants were randomly allocated into three groups (G1, G2, and G3) undergoing
222 three treatment periods (t1-t3). During each period, each group received treatment
223 with the same osteopathic technique but applied by another practitioner to another
224 muscle. Over the course of the trial, all three groups were treated (1) with all three
225 osteopathic techniques (MRT, MET, and SST); (2) at all three muscles (CS, SM, and

226 UT); and (3) by all three practitioners (P1, P2, P3). However, the muscle-technique-
 227 practitioner combination was distinct for each group during each period (Table 1).
 228 All interventions and measurements were applied (1) to the right side of the
 229 participant's body to ensure comparability, and (2) in relaxed supine position to
 230 maintain resting muscle state. The trial comprised one-week washout periods
 231 between baseline (t0) and each session (t1-t3). A session consisted of one
 232 intervention day which encompassed 5 minutes of measurement, followed by 5
 233 minutes of treatment, and renewed 5 minutes of measurement per subject.
 234 Participants started with 5 minutes delay to one another to allow measurement by
 235 one assessor who was not involved with the interventions. In this trial, all groups
 236 were intervention groups that were treated at one muscle per session, while all
 237 three muscles were measured. Thus, measures from untreated muscles were used
 238 as control values (Table 2).

239

240 Table 1 | Trial procedure

241

		G1	G2	G3
Period 1	<i>Technique:</i>	MRT	MRT	MRT
	<i>Muscle:</i>	UT	SM	CS
	<i>Therapist:</i>	P2	P1	P3
Period 2	<i>Technique:</i>	MET	MET	MET
	<i>Muscle:</i>	SM	CS	UT
	<i>Therapist:</i>	P3	P2	P1
Period 3	<i>Technique:</i>	STT	STT	STT
	<i>Muscle:</i>	CS	UT	SM
	<i>Therapist:</i>	P1	P3	P2

242

243

244

Legend: P1 = practitioner 1; P2 = practitioner 2; P3 = practitioner 3; MRT = myofascial release technique; MET = muscle energy technique; STT = soft tissue technique; CS = corrugator supercilii muscle; SM = superficial masseter muscle.

245 **Table 2 | Controls**
246

Period 1	G1	CS (control)
		SM (control)
		UT (intervention)
	G2	CS (control)
		SM (intervention)
		UT (control)
	G3	CS (intervention)
		SM (control)
		UT (control)
Period 2	G1	CS (control)
		SM (intervention)
		UT (control)
	G2	CS (intervention)
		SM (control)
		UT (control)
	G3	CS (control)
		SM (control)
		UT (intervention)
Period 3	G1	CS (intervention)
		SM (control)
		UT (control)
	G2	CS (control)
		SM (control)
		UT (intervention)
	G3	CS (control)
		SM (intervention)
		UT (control)

247 **Legend:** shaded boxes = intervention (treated muscles); non-shaded boxes = controls (untreated muscles). **Explanation:** During
248 each period, the groups (G1, G2, G3) were treated at one muscle (intervention) while the other two muscles remained
249 untreated (control). However, all three muscles were measured. Thus, the measures of the untreated muscles were used as
250 control values for the treated muscles. For example, in period 1, G1 was treated (and measured) at the UT, whereas the UT
251 was not treated (but measured) in G2 or G3. Hence, the control values for the treated muscle in each group were generated
252 by the untreated muscles in the other two groups.
253

254 **Participants:**

255 Three undergraduate classes of osteopathy students were recruited from the
256 Osteopathie Schule Deutschland in Hamburg, Germany. The sample was limited to
257 healthy subjects from this specific setting. The eligibility criteria were specified to
258 include participants between 18 and 50 years old and exclude participants with
259 health complaints (particularly muscle disorders) to minimise the risk of age- [104,
260 105] and disease-related [106] changes of the musculature.

261 **Interventions:**

262 Three manual techniques from the osteopathic field (MRT, MET, and STT) were
263 selected and administered for ~5 minutes. These osteopathic techniques were
264 applied with the aim of modifying the HRMT in healthy participants and were
265 adjusted to fit the structure and function of each muscle. A consensus training was
266 implemented prior to the trial to ensure that all therapists applied the interventions
267 coherently. During the first session, MRT was applied to the right CS (G3), SM (G2),
268 and UT (G1). During the second session, MET was applied to the right CS (G2), SM
269 (G1), and UT (G3). During the third session, STT was applied to the right CS (G1), SM
270 (G3), and UT (G2) (Table 1). Overall, the interventions were chosen to represent
271 the broad range of osteopathic techniques and their diverse characteristics
272 comprising: (1) direct, indirect, and combined techniques; (2) active and passive
273 techniques; and (3) techniques with high- and low-pressure or counterforce [32,
274 107].

275 ***Myofascial Release Technique (MRT):***

276 MRT is an indirect (or direct) and passive technique using low pressure. The muscle
277 is palpated (covering origin and insertion) and guided alongside the path of least
278 resistance into a position of ease [108], thereby following the tissues' micro-
279 movements away from the restricted barrier until a release occurs (Figure 1).

280 ***Muscle Energy Technique (MET):***

281 MET is a direct and active technique using counterforce. The therapist brings the
282 muscle into a position of stretch and holds it at the restriction barrier. The
283 participant then performs an isometric contraction of the muscle (with 25% of

284 maximum effort/force) away from this restricted barrier and against the therapist's
285 counterforce [109]. After approximately 3-6 seconds of contraction, the participant
286 relaxes, and the therapist adjusts the tissue towards its renewed
287 movement/restriction barrier while following the tissue's micro-movements. This
288 post-isometric relaxation approach is repeated 3-6 times (**Figure 1**).

289 *Soft Tissue Technique (STT):*

290 STT is a direct and passive technique using high pressure. The therapist applies
291 repeated longitudinal deep pressure gliding strokes with the thumb alongside the
292 muscle fibres of the CS (from origin towards insertion), SM (from origin towards
293 insertion), and UT (from insertion towards origin). This is similar to the treatment
294 of a trigger band according to the fascial distortion model [110] but is applied to
295 palpably firm muscle fibres and their fascial surroundings (**Figure 1**).

296

297 **Figure 1 was removed from the preprint due to identifying information**

298 **Figure 1** | Osteopathic techniques; **Legend:** red arrows = therapists' motion; black arrows =
299 participants' motion; four-headed arrows = motion applied in all directions.

300

301 **Outcomes:**

302 We used the handheld digital palpation device MyotonPRO [Version 5.0.0] as the
303 outcome measure (**Figure 2**). This myotonometer assesses the muscle's tone,
304 biomechanical and viscoelastic properties using five parameters by means of
305 dynamic oscillation mechanosignals [81, 111] (**Table 3**). The MyotonPRO is a valid
306 and reliable measurement tool for healthy and diseased participants [112, 113] (**Box**

307 4) that has been applied to evaluate muscle tone, muscle stiffness, and HRMT in
 308 multiple studies investigating various structures and conditions [71, 81, 93, 114-
 309 116]. The myotonometer measurements were carried out at all three sessions (t1-
 310 t3) before and after the treatment intervention. Measurement points (MPs) were
 311 predefined for the myotonometer measurements of each muscle prior to the trial
 312 (Box 5). MPs were identified by manual palpation following anatomical landmarks.
 313 All MPs were marked before each session using a dermatological skin marker pen.

314

315 **Figure 2 was removed from the preprint due to identifying information**

316 **Figure 2 | MyotonPRO; Legend: Not applicable.**

317

318 **Table 3 | MyotonPRO parameters**

319

Parameter	Description	Formula
F - Oscillation Frequency	Measures the muscle's tone in resting state (excluding voluntary contractions like depicted within an EMG measurement) in Hertz (Hz)	$F = f_{max}$
S - Dynamic Stiffness	Measures the biomechanical property of a muscle to deform its shape under internal or external force in Newton meter (N/m)	$S = \frac{a_{max} \cdot m_{probe}}{\Delta l}$
D - Logarithmic Decrement	Measures the elasticity characterized by the muscle's natural oscillation (which represents the biomechanical ability to regain its initial shape after deformation under internal or external force)	$D = \ln\left(\frac{a_1}{a_3}\right)$
R - Mechanical Stress Relaxation Time	Measures the time the muscle tissue needs to recover its shape after deformation under internal or external force in milliseconds (ms)	$R = t_R - t_1$
C - Ratio of deformation and Relaxation time	Measures the gradual elongation of muscle tissue over time under constant tensile stress	$C = \frac{R}{t_1 - t_T}$

320

321 **Box 4 | Validity and reliability of the MyotonPRO**

322 The MyotonPRO shows good validity and high reliability for measuring, for example, the trapezius muscle [117]. In detail,
 323 studies demonstrate moderate to excellent inter-rater reliability (intra-class correlation coefficient [ICC] for F = 0.87, S =
 324 0.79, D = 0.93, R = 0.65, C = 0.50; standard error of measurement [SEM] for F = 0.7, S = 16.8, D = 0.2, R = 1.4, C = 0.1),
 325 moderate to good intra-rater reliability (ICC for F = 0.81, S = 0.82, D = 0.76, R = 0.74, C = 0.52; SEM for F = 0.8, S = 16.9, D =
 326 0.2, R = 1.2, C = 0.1) [118], and good to excellent test-retest reliability (ICC for S = 0.821-0.913; SEM for S = 23.59) [119].

327

328 **Box 5 | Measurement points (MPs)**

329 The MP for the: (1) CS was determined to be located 0.5 cm superior to the supraorbital notch slightly above the eyebrow
330 [120, 121]; (2) SM was determined to be located just below the midpoint of a virtual line between the muscle's origin and
331 attachment (masseteric tuberosity of the mandibular angle and the tendinous aponeurosis at the anterior third of the
332 zygomatic arch) [122, 123]; and (3) UT was determined to be located halfway between a virtual line from the top of the
333 acromion to the spinous process of C7 (which is - 19.5 cm) [81, 124] (notably, MPs were inspired, not determined, by the cited
334 references).

335

336 **Sample size:**

337 The sample size was calculated prospectively using G*Power, which is a power
338 analysis for ANOVA with repeated measures (within-between interaction) [125, 126].
339 We assumed a type I error level of 0.05 and statistical power of 95%. Based on an
340 estimated partial η^2 of 0.1 (unpublished data), an effect size of 0.33, and three
341 measurements and four groups, a total sample size of 52 participants was calculated.
342 Using an estimated drop-out rate of 15%, the sample size was planned with 60
343 participants.

344 **Randomisation:**

345 The sample was randomly allocated into three groups (G1, G2, G3) by block
346 randomization (1:1:1 allocation ratio) using computer-generated allocation schedule
347 (<http://www.randomization.com>). Furthermore, we randomly assigned which
348 technique would be applied in which period by throwing the dice. Afterwards, we
349 randomly assigned the muscles and therapists to the groups and periods in the same
350 manner. The principal investigator generated the random allocation sequence,
351 enrolled participants, and assigned them to sequences of intervention while having
352 no clinical involvement in the trial. Treatments were scheduled according to

353 allocation sequence and therapists and participants were first introduced to each
354 other during the respective sessions.

355 **Blinding:**

356 Participants and statisticians, but not therapists and assessors, were blinded to the
357 conditions. However, we assume that blinding was compromised because the
358 participants were osteopathy students that were likely able to distinguish between
359 the interventions.


360 **Statistical methods:**

361 The outcomes from myotonometer measurements were assessed by calculating the
362 within-participant difference of each parameter for all groups between t1 and t3
363 (primary objective) and the between-participant difference of each parameter for
364 each group between pre- and post-treatment of each session (secondary objective).
365 Statistical analysis was conducted by employing the software R Studio.
366 Myotonometer properties (F, S, D, R, and C) were used as parameters and converted
367 into factors. Heidelberger & Welch's diagnostic was used to run length diagnostic
368 and convergence diagnostic. The descriptive statistic for the primary objective was
369 presented by mean, standard deviation, and quantiles, whereas the secondary
370 objective was presented by standard deviation, quantiles, and simple effect. Due to
371 the limitations of standard repeated measures ANOVA for categorical variables and
372 unbalanced data, the inductive statistics for the primary and secondary objectives
373 as well as subgroup analysis were calculated using the Bayesian version of the
374 repeated-measures analysis of variance (BANOVA) [127]. The p-values of the
375 multiple comparisons were adjusted using the Bayesian model [128]. The

376 significance level was set to 5% ($p \leq 0.05$). Missing completely at random values were
377 included for further analysis. Missing at random and missing not at random values
378 were excluded as they are dependent on one factor and bias the results [129].

379 RESULTS

380 Overall, 82 participants were screened and 23 declined to participate or had
381 scheduling issues. The remaining 59 participants were randomly allocated into
382 groups, leading to a sample of 20 participants for groups G1 and G2, and 19
383 participants for the G3 group. Two participants from group G3 cancelled their
384 participation in the study due to personal reasons and were excluded from
385 interventions and analysis prior to the first period. Therefore, the first trial period
386 started with the final sample size ($n=57$) distributed across groups as follows: G1
387 ($n=20$), G2 ($n=20$), and G3 ($n=17$). Unfortunately, some participants missed
388 scheduled appointments and thereby allocated interventions and measurements.
389 These participants were not excluded from study participation and data was
390 included for analysis unless all three periods were missed, which did not occur. In
391 detail, appointments were missed during the: (1) first period by two participants
392 from group G1 and one participant from group G2; (2) second period by three
393 participants from group G3; and (3) third period by five participants from group G1,
394 two participants from group G2, and two participants from group G3 (Figure 3).



395

396 **Figure 3 | Participant flow chart; Legend: Not applicable.**

397 **Recruitment:**

398 Participants were recruited, provided written informed consent, and reported
 399 baseline data in December 2019. The trial was implemented over the course of one
 400 month between January and February 2020.

401 **Baseline data:**

402 Baseline demographics were recorded and included sex, handedness, age, and body
 403 mass index (BMI). The sample was predominantly female (68%), right-handed (91%),
 404 young (22.7 ± 4.5 years), and of normal weight (22.0 ± 2.5 BMI) (Table 4).

405

406 **Table 4 | Baseline demographics**

Parameter	G1 (n=20)		G2 (n=20)		G3 (n=17)	
	<i>R</i>	%	<i>R</i>	%	<i>R</i>	%
F:M	14:6	70	13:7	65	12:5	71
RH:LH	16:4	80	19:1	95	17:0	100
	<i>Mean</i>	<i>SD</i>	<i>Mean</i>	<i>SD</i>	<i>Mean</i>	<i>SD</i>
Age	22.0	1.7	21.4	2.7	25.1	7.0
BMI	21.8	1.7	21.3	2.1	23.2	3.4

407 Legend: F = female; M = male; RH = right-handed; LH = left-handed; R = ratio; SD = standard deviation.

408

409 **Numbers analysed:**

410 The data were examined for availability and normality to rule out statistical errors
 411 during analysis. Overall, 8.9% of the collected data did not correspond to the
 412 confidence interval of the MyotonPRO (set to 90%) and was thus not available for
 413 analysis. All missing values arose from measurements of the CS, demonstrating that
 414 the data was not missing at random. The CS was consequently excluded from analysis
 415 because correct coefficient estimation was not guaranteed. After exclusion, data

416 from 104 treatments (54 for SM and 50 for UT) were included for analysis (104 of 156
417 measures).

418 **Outcomes:**

419 Here, full outcome data are reported (**Table 5**). Subsequently, results will be
420 presented (excluding the CS) according to the primary and secondary objectives.

424 Table 5 | Results - Outcomes

			F	S	D	R	C	F	S	D	R	C	F	S	D	R	C	
MRT	CS	pre	mean	31.24	1398.50	1.79	6.03	0.62	32.17	1565.75	1.72	5.70	0.60	32.09	1445.75	1.70	5.87	0.64
			SD	2.61	224.15	0.12	0.73	0.52	4.96	35.09	0.14	0.83	0.05	4.24	142.66	0.11	0.65	0.07
		post	mean	32.73	1301.67	1.72	6.18	0.61	32.14	1352.83	1.74	6.07	0.61	33.35	1367.63	1.75	6.02	0.62
			SD	3.85	293.65	0.11	1.15	0.07	3.25	197.70	0.11	0.83	0.06	3.43	179.33	0.11	0.89	0.06
	SM	pre	mean	14.24	265.11	1.60	22.65	1.40	13.90	270.47	1.67	22.22	1.38	14.09	264.44	1.62	22.72	1.41
			SD	1.73	49.29	0.23	3.20	0.16	1.36	34.34	0.16	2.63	0.15	1.24	39.49	0.21	3.21	0.18
		post	mean	14.08	262.78	1.59	22.96	1.41	13.79	257.40	1.62	22.97	1.42	13.97	260	1.59	23.01	1.43
			SD	1.49	47.98	0.26	2.55	0.13	0.97	32.10	0.19	2.76	0.16	1.23	34.67	0.18	3.06	0.18
	UT	pre	mean	12.11	193.53	1.16	26.48	1.56	11.72	167.73	0.99	27.44	1.56	11.68	171.06	1.01	27.52	1.56
			SD	0.97	30.18	0.25	2.60	0.15	0.64	20.28	0.12	2.39	0.19	0.93	33.65	0.18	1.93	0.10
		post	mean	11.93	184.29	1.10	26.61	1.52	11.62	170.84	1.00	27.78	1.60	11.54	172.22	1.03	28.13	1.61
			SD	0.88	37.03	0.21	2.62	0.20	0.69	21.53	0.11	2.16	0.13	0.87	29.76	0.15	2.13	0.09
MET	CS	pre	mean	33.37	1370.75	1.79	6.19	0.62	33.04	1376.33	1.82	6.28	0.62	31.56	1311	1.81	6.01	0.63
			SD	3.11	193.16	0.09	0.68	0.04	3.85	169.39	0.08	1.03	0.06	2.96	20.04	0.11	0.64	0.05
		post	mean	32.81	1325.40	1.74	6.39	0.64	32.67	1378.13	1.83	6.15	0.63	33.05	1504.50	1.80	6.28	0.63
			SD	3.58	205.99	0.12	1.09	0.07	4.42	199.35	0.10	0.88	0.07	5.24	167.61	0.13	0.67	0.04
	SM	pre	mean	13.98	283.85	1.79	20.93	1.30	13.79	257.40	1.62	22.97	1.42	13.96	267.50	1.67	22.95	1.44
			SD	1.07	31.12	0.18	2.52	0.15	0.97	31.25	0.20	2.68	0.16	1.03	32.69	0.17	2.62	0.15
		post	mean	13.95	283.15	1.75	21.19	1.32	11.75	252.35	1.61	23.86	1.48	14.13	270.71	1.65	22.52	1.40
			SD	1.12	33.46	0.15	2.48	0.15	1.03	37.04	0.20	2.88	0.17	1.23	32.04	0.21	2.47	0.15
	UT	pre	mean	11.71	170.45	1.01	27.41	1.55	11.51	171.95	1.03	28.09	1.60	11.84	182.21	1.08	27.45	1.60
			SD	0.83	26.19	0.11	1.92	0.12	0.89	28.44	0.15	2.36	0.14	0.89	23.43	0.21	2.62	0.14
		post	mean	11.55	169.05	1.01	27.95	1.58	11.31	168.6	1.05	28.60	1.62	11.75	181.93	1.13	27.61	1.60
			SD	0.83	26.65	0.13	2.19	0.13	0.81	28.09	0.15	2.30	0.14	0.89	27.18	0.26	3.00	0.17
STT	CS	pre	mean	33.29	1475.50	1.77	6.02	0.61	35.25	1472.25	1.81	5.54	0.60	33.77	1387.86	1.75	6.22	0.62
			SD	3.83	239.40	0.09	0.77	0.06	4.28	82.05	0.11	0.40	0.05	3.78	128.75	0.12	0.70	0.05
		post	mean	33.61	1402.60	1.78	6.04	0.62	35.05	1428.50	1.77	5.84	0.61	34.39	1440.33	1.77	5.82	0.61
			SD	4.45	140.40	0.07	0.64	0.04	5.17	228.56	0.10	0.75	0.04	4.12	196.24	0.10	0.65	0.04
	SM	pre	mean	13.97	262.87	1.65	22.56	1.40	13.80	265.67	1.70	22.85	1.42	13.87	266.78	1.67	22.43	1.40
			SD	0.89	29.16	0.24	2.52	0.15	1.08	26.10	0.19	2.10	0.13	1.24	27.23	0.15	2.44	0.14
		post	mean	13.88	259.13	1.62	22.87	1.42	13.78	254.2	1.64	22.99	1.42	13.72	261.39	1.63	22.99	1.44
			SD	0.90	31.03	0.23	2.77	0.16	1.23	30.57	0.22	2.42	0.13	1.11	27.31	0.15	2.47	0.14
	UT	pre	mean	11.49	176.53	1.04	28.39	1.64	11.81	188.2	1.10	27.40	1.62	11.66	174.00	1.02	27.85	1.61
			SD	0.97	26.21	0.15	3.27	0.20	0.53	21.09	0.23	1.53	0.09	0.83	17.21	0.11	2.02	0.14
		post	mean	11.55	176.27	1.04	27.63	1.57	11.77	189.20	1.11	27.51	1.63	11.38	174.00	1.09	28.96	1.70
			SD	1.00	35.47	0.17	2.80	0.18	0.53	21.23	0.19	1.59	0.10	0.68	12.62	0.15	1.87	0.10

Legend: yellow = G1; blue = G2; green = G3; darker colouring = treated muscles (intervention values); lighter colouring = untreated muscles (control values). Abbreviations: MRT = myofascial release technique; MET = muscle energy technique; STT = soft tissue technique; CS = corrugator supercilii muscle; SM = superficial masseter muscle; UT = upper trapezius muscle; pre = before intervention; post = after intervention; SD = standard deviation; F = Oscillation Frequency; S = Dynamic Stiffness; D = Logarithmic Decrement; R = Mechanical Stress Relaxation Time; C = Ratio of deformation and Relaxation time.

425
426
427
428
429

430 *Outcomes for the primary objective:*

431 The outcomes for the primary objective were assessed by means of the standardized
 432 mean difference. The data passed all of Heidelberg's and Welch's convergence
 433 diagnoses and showed that: F (-0.163 [0.060]; p=0.008), S (-3.060 [1.563]; p=0.048),
 434 R (0.594 [0.141]; p<0.001), and C (0.038 [0.017]; p=0.028) changed significantly,
 435 while D (0.011 [0.017]; p=0.527) did not change significantly (Table 6). In other
 436 words, muscle tone (F [p=0.008]) and biomechanical properties (S [p=0.048] not D
 437 [p=0.527]) decreased, while the viscoelastic properties (R [p<0.001] and C
 438 [p=0.028]) increased. Subgroup analysis for sex-specific changes revealed a
 439 significant interaction for F (-0.192 [0.089]; p=0.030), but not for S (0.008 [0.0125];
 440 p=0.510), D (0.008 [0.013]; p=0.555), R (-0.423 [0.218]; p=0.057), and C (-0.019
 441 [0.015]; p=0.237) (Table 6).

442

443 **Table 6 | Results - Outcomes for the primary objective**

Parameter	Gender	Mean	SD	Quantile		p-value
				0.025	0.075	
F	total	-0.163	0.060	-0.278	-0.045	0.008 *
	female	-0.209	0.073	-0.344	-0.059	0.003 *
	male	-0.106	0.116	-0.335	0.120	0.345
S	total	-3.060	1.563	-6.187	-0.011	0.048 *
	female	-4.152	1.831	-7.707	-0.540	0.023 *
	male	-1.305	2.829	-6.747	4.310	0.628
D	total	0.011	0.017	-0.022	0.045	0.527
	female	0.018	0.012	-0.006	0.040	0.120
	male	-0.001	0.013	-0.026	0.024	0.906
R	total	0.594	0.141	0.311	0.873	<0.001 *
	female	0.678	0.182	0.321	1.044	<0.001 *
	male	0.471	0.256	-0.041	0.983	0.074
C	total	0.038	0.017	0.004	0.071	0.028 *

female	0.045	0.013	0.020	0.071	<0.001 *
male	0.029	0.015	-0.001	0.059	0.059

444 Legend: F = Oscillation Frequency; S = Dynamic Stiffness; D = Logarithmic Decrement; R = Mechanical Stress Relaxation Time;
 445 C = Ratio of deformation and Relaxation time; SD = standard deviation; * = p<0.05.
 446

447 **Outcomes for the secondary objective:**

448 Since there was a significant interaction between treatment and muscle (0.037
 449 [0.014]; p=0.009), the simple effects were interpreted for the secondary objective.
 450 There was a tendency for a difference in comparison between MRI, MET and STT,
 451 but all multiple comparisons between treatment and muscle were not significant
 452 (p>0.05) (Table 7). There was no sex-specific simple effect for the significant
 453 interaction but some tendency (p>0.05). For example, in males compared to
 454 females, F of the UT showed a higher increase and decrease following MET and MRT,
 455 respectively (Table 8) (Figure 4) (Figure 5).

456

457 Table 7 | Results - Outcome for the secondary objective
 458

Parameter	Muscle	Treatment	Simple effect	SD	Quantile 0.025	Quantile 0.975	p-value
F	SM	MET	-0.084	0.121	-0.320	0.147	0.498
		MRT	-0.061	0.120	-0.307	0.171	0.598
		STT	0.146	0.126	-0.100	0.395	0.244
	UT	MET	0.073	0.132	-0.189	0.325	0.577
		MRT	0.046	0.124	-0.199	0.293	0.695
		STT	-0.120	0.124	-0.372	0.117	0.324
S	SM	MET	1.359	2.916	-4.366	6.992	0.641
		MRT	3.633	2.872	-1.979	9.215	0.202
		STT	-4.992	3.127	-11.151	1.225	0.111
	UT	MET	-0.578	3.248	-6.974	5.739	0.851
		MRT	0.921	2.984	-4.995	6.868	0.758
		STT	-0.343	3.057	-6.367	5.716	0.915
D	SM	MET	0.016	0.031	-0.044	0.076	0.620
		MRT	0.019	0.031	-0.042	0.081	0.521
		STT	-0.036	0.033	-0.102	0.029	0.281
	UT	MET	-0.002	0.034	-0.070	0.065	0.934
		MRT	-0.018	0.033	-0.086	0.046	0.573
		STT	0.021	0.033	-0.045	0.086	0.530
		MET	0.329	0.268	-0.188	0.859	0.216

R	SM	MRT	0.081	0.275	-0.447	0.609	0.777
		STT	-0.411	0.288	-0.984	0.157	0.156
	UT	MET	-0.468	0.303	-1.079	0.124	0.115
		MRT	-0.016	0.294	-0.592	0.575	0.960
		STT	0.485	0.282	-0.067	1.026	0.086
		MET	0.021	0.031	-0.029	0.073	0.432
C	SM	MRT	0.019	0.032	-0.030	0.064	0.483
		STT	-0.041	0.041	-0.087	0.518	0.224
		MET	-0.028	0.022	-0.076	0.026	0.395
	UT	MRT	-0.020	0.019	-0.072	0.032	0.428
		STT	0.049	0.028	-0.002	0.099	0.197
		MET					

Legend: F = Oscillation Frequency; S = Dynamic Stiffness; D = Logarithmic Decrement; R = Mechanical Stress Relaxation Time; C = Ratio of deformation and Relaxation time; SM = superficial masseter muscle; UT = upper trapezius muscle; SD = standard deviation.


459
460
461
462

463 **Table 8 | Sex-specific analysis of frequency**

Gender	Muscle	Treatment	Mean	Quantile		p-value
				0.025	0.075	
female	SM	MET	-0.203	-0.526	0.117	0.999
		MRT	-0.417	-0.771	-0.064	0.189
		STT	-0.083	-0.463	0.284	0.506
	UT	MET	-0.259	-0.675	0.149	0.443
		MRT	0.025	-0.315	0.365	0.177
		STT	-0.274	-0.620	0.069	0.637
male	SM	MET	-0.369	-0.915	0.168	0.276
		MRT	0.101	-0.404	0.604	0.199
		STT	0.107	-0.525	0.723	0.411
	UT	MET	0.222	-0.371	0.798	0.195
		MRT	-0.400	-0.932	0.131	0.199
		STT	-0.296	-0.826	0.248	0.407

Legend: SM = superficial masseter muscle; UT = upper trapezius muscle; SD = standard deviation. P-value for the simple effects.


464
465



466

467 **Figure 4** | Mean differences in frequency of UT for MET; **Legend:** Not applicable.

468



469

470 **Figure 5** | Mean differences in frequency of UT for MRT; **Legend:** Not applicable.

471

472 **Harms:**

473 Participants were instructed to report harms to their physical or mental health to
474 the principal investigator by phone or e-mail, pending their severity. No harms were
475 reported.

476 **DISCUSSION**477 **Findings:**

478 To the best of our knowledge, this study is the first to investigate the immediate
479 effect of OMT on the HRMT of healthy subjects. In detail, we used biomechanical
480 and viscoelastic measures to assess the effect of manual techniques with different
481 modalities on muscles with different characteristics. The sample comprised 57
482 participants (computed: 60; screened: 82; randomised 59) and showed acceptable
483 recruitment and retention rates (72% and 96%, respectively). First, we report
484 significant results for the primary objective (main effect). In detail, MET, MRT, and
485 STT applied to the SM and UT (CS was excluded) resulted in significantly decreased
486 muscle tone (F [p=0.008]), decreased biomechanical (S [p=0.048] not D [p=0.527]),
487 and increased viscoelastic properties (R [p<0.001] and C [p=0.028]) from baseline to
488 follow-up (compared to the same, but untreated, muscles of subjects from other
489 groups) (**Table 6**). Notably, decrement (D [p=0.527]) did not change significantly,
490 however, this muscle parameter was previously proposed to be a constant [130]. The
491 data suggest that the primary hypothesis can be confirmed, showing that osteopathic
492 techniques modulated the HRMT of treated muscles in healthy subjects by
493 decreasing muscle tone and stiffness while increasing relaxation and creep
494 (decrement did not change significantly). Second, we demonstrate no significant
495 results for the secondary objective (interaction effect). However, we detected a

496 non-significant trend ($p>0.05$) suggesting that the decrease in muscle tone (F),
497 decrease in biomechanical (D not S), and increase in viscoelastic properties (R and
498 C) were achieved through MET and MRT (not STT) when applied to the SM, and
499 through STT (not MET and MRT) when applied to the UT (**Table 7**). Notably, this
500 tendency was consistent for all muscle properties except for muscle stiffness (S). In
501 other words, the smaller and thinner muscle (SM) responded (as expected) to the
502 active (MET) and low-pressure technique (MRT), whereas the larger and thicker
503 muscle (UT) responded (as expected) to the high-pressure technique (STT). The
504 reported trend is fairly consistent with the secondary hypothesis (considering that
505 the CS was excluded) but requires further scrutiny for verification or falsification.
506 Lastly, subgroup analysis for the main effect revealed a significant sex-specific
507 difference for muscle tone ($p=0.030$) but no other muscle properties ($p>0.05$).
508 Overall, female subjects showed greater descriptive changes (mean values for
509 primary objective) in all muscle properties than male subjects (**Table 6**). For the
510 interaction effect, no significant sex-specific difference was found but an interesting
511 tendency showed that the muscle tone of the UT increased after MET and decreased
512 after MRT in males, whereas the opposite was reported for females (**Table 8**) (**Figure**
513 **4**) (**Figure 5**). The reason for this trend is unclear but we hypothesise, based on
514 clinical experience, that males tend to exaggerate the counterpressure during MET
515 techniques (presumably to demonstrate strength) which may have increased muscle
516 tone.

517 **Mechanisms:**

518 To date, the mechanisms underlying these reported changes in HRMT following OMT
519 are unclear and require further investigation. There might be biological,
520 psychological, and social factors involved. However, based on the context of this

521 study (comprising a short treatment time, strong manual focus, and unsound
522 therapeutic alliance), we speculate that a biological mechanism of action is most
523 probable. Though it might be the case that the three techniques have the same,
524 different, overlapping, or multiple mechanisms of action (**Box 2**), we suggest that
525 mechanotransduction may underlie these changes. In detail, mechanotransduction
526 suggests that extracellular mechanical signals are converted into intracellular
527 chemical signals (and changes in gene expression) via integrins, which physically
528 couple the extracellular matrix (including collagen fibres) with the intracellular
529 cytoskeleton (including actomyosin filaments) [131]. As the HRMT depends on the
530 interaction of cellular actomyosin filaments [79], we hypothesise that mechanical
531 stimuli provided within osteopathic treatment may change the tensional forces
532 within the (collagen fibres of the) extracellular matrix and, through integrins, within
533 the (actomyosin filaments of the) intracellular cytoskeleton, thereby modifying the
534 HRMT.

535 **Comparison:**

536 Overall, there is a scarcity of studies assessing the effect of manual treatment on
537 muscle properties. Moreover, the available literature is focused on muscle stiffness
538 and tone, whereas decrement, relaxation, and creep are mostly not considered.
539 Therefore, our findings complement the existing body of evidence. Taking these
540 factors into account, our results are largely consistent with the current literature.
541 For example, in healthy participants, it was shown that manual therapy can reduce
542 muscle stiffness [132]; this was demonstrated for MET [133], MRT (or self-MRT,
543 respectively, which mimics manual MRT with a foam roller) [134], and STT (or
544 massage, respectively, which resembles STT using deep pressure gliding strokes)
545 [135]. Similarly, it was revealed that trigger points have an increased muscle tone

546 and stiffness [113], which can be decreased through manual myofascial release
547 [136]. Notably, manual techniques might also reduce muscle tone and stiffness in
548 participants with MSDs [137]. Particularly in patients with LBP, increased
549 paravertebral muscle tone and stiffness were demonstrated [138], which could be
550 reduced through manual techniques like spinal mobilisation [139]. However, further
551 research is required to substantiate these findings. Beyond that, we need to consider
552 other factors that could have swayed the results, such as gender, age, and
553 handedness. The sample in this study was relatively homogenous comprising
554 predominantly female (68%), young (22.7 ± 4.5 years), and right-handed (91%)
555 subjects. In general, muscle tone and stiffness are reported to be greater in males
556 than females [140-142], however, there are also conflicting findings [105].
557 Nonetheless, higher muscle tone and stiffness in males may arise due to differences
558 in the composition of muscle fiber types between the genders [143] as well as
559 physiological varieties in muscle size, mass, and conditioning [130]. Besides gender,
560 significant differences in muscle stiffness have also been reported between age
561 groups (higher in elderly and middle-aged than young individuals) [142] and
562 handedness (higher on the side of the dominant hand) [141]. Although subgroup
563 analysis was performed for gender, we did not consider the impact of age (because
564 only two subjects were over thirty years old) and handedness (because all measures
565 were taken on the right side and only five subjects were left-handed).

566 **Limitations:**

567 There are limitations to consider when interpreting the results of this study. First
568 and foremost, one of the three conditions was dropped because of frequent
569 measurement errors. In detail, all missing values (8.9% of all numbers analysed)
570 originated from myotonometer measurements of the CS (not SM or UT), which was

571 consequently excluded from the analysis. These dependent missing values limited
572 the number of observations available to analysis and therefore reduced the
573 statistical power [144]. Further, dropping one condition increases the likelihood of
574 reporting false-positive results [145]. Presumably, these missing values arose
575 because the feasibility of the MyotonPRO is limited to measurements of muscles that
576 are thicker than 3mm [111] and not located near the bone [146, 147] (**Box 6**).

577

578 **Box 6 | CS characteristics**

579 Prior to the trial, we reviewed the literature on the thickness of the CS, which was reported with a mean maximum thickness
580 of 5.50 ± 0.91 mm in healthy subjects [94]. However, because the measurements of the CS were frequently inconsistent, we
581 reviewed the literature again and found other studies accounting for an average thickness of approximately 1.62 ± 0.4 mm
582 [97], 2-3 mm [148], and -2.4-2.8 mm [149], respectively. Thus, we acknowledge a flaw in our initial literature search and
583 suggest that the CS may be too thin and/or near the bone to be consistently measured using the MyotonPRO.

584

585 Another shortfall is that the results are merely informative of an immediate-term
586 effect (approximately five minutes after treatment). Thus, the measured tissue
587 response may be reflective of the thixotropy effect [150]; albeit the size of this
588 effect remains unclear [151]. Further, it is noteworthy that participants were
589 assessed in supine position although the HRMT relates to the biotensegrity system
590 and posture [79]. Other barriers to interpreting the results relate to the
591 interventions. For one, manual techniques are often loosely defined, and it was
592 particularly difficult to find literature describing the same manual procedure as the
593 STT used in this study. In the end, we settled to include research on massage
594 techniques, which employ similar parameters than the STT. Future research might
595 consider not examining manual techniques (e.g., MET, MRT, and STT) but rather
596 their biophysical parameters (e.g., stretch, compression, shear, and torque forces)
597 to ensure optimal comparability [152, 153]. Furthermore, the manual techniques

598 were applied for five minutes, which appears brief but seems to be sufficient for
599 one muscle to be treated with one technique (because the therapists perceived
600 palpatory signs of release/relaxation). Also, we cannot rule out therapist-specific
601 differences in outcomes, although consensus training was implemented. Moreover,
602 the interventions encompassed common manual techniques with different
603 characteristics, however, single manual techniques are not representative of
604 person-centered osteopathic care.

605 **Future directions:**

606 Future studies might assess the effect of OMT on the HRMT of people with MSDs
607 because conditions like LBP and NP are associated with altered muscle properties
608 [116, 138, 154]. For example, in patients with LBP compared to healthy controls,
609 the lumbar extensor myofascia generally shows increased muscle tone (F), stiffness
610 (S), and decrement (D) [141, 154-156] as well as decreased relaxation (R) and creep
611 (C) [138, 157, 158]. Hence, we propose to examine the effect of OMT on the muscle
612 properties of, for example, the lumbar extensor myofascia or the upper trapezius
613 muscles in patients with LBP or NP, respectively. Based on the present findings, we
614 hypothesise that osteopathic interventions will decrease muscle tone, stiffness, and
615 decrement, and increase relaxation and creep in this population. However, future
616 studies are needed to validate or falsify this hypothesis. Another consideration for
617 future research is that muscle properties like stiffness do not seem to correlate with
618 pain (in patients with chronic NP and LBP), because muscle stiffness typically returns
619 to baseline one day after treatment (using cupping massage) even if the pain
620 improves [159]. Lastly, it is unclear if OMT could also have the opposite effect. In
621 detail, it has previously been assumed that OMT restores normal muscle tone where
622 it is altered [73-76], meaning that high muscle tone decreases, and low muscle tone

623 increases, when OMT is applied [83]. Therefore, it might be useful to assess the
624 effect of OMT on conditions associated with both hypertonia and hypotonia. Lastly,
625 future research should assess if these changes are enduring in the short, medium,
626 and long term.

627 **Interpretation:**

628 In this study, we demonstrate that OMT modifies the HRMT in healthy participants
629 without significant interaction of muscle-technique pairs. The mechanisms
630 underlying these changes are unclear and the results are limited by the exclusion of
631 one condition. Our findings are largely consistent with previous research but merely
632 informative of an immediate effect. Future studies should modify the protocol and
633 assess if these effects are reproducible (and beneficial) in patients with MSDs. In the
634 end, although speculative, we hypothesise that modifying the HRMT may be a
635 mechanism of action underlying manual techniques.

636 **CONCLUSION**

637 Taken together, we built on research suggesting that alterations of the HRMT may
638 underlie MSDs and respond to OMT. Taken together, we report that osteopathic
639 techniques (MRT, MET, and STT) significantly decreased muscle tone (F), decreased
640 biomechanical (S not D), and increased viscoelastic properties (R and C) of the SM
641 and UT (CS was not measurable) at immediate term. Hence, osteopathic modalities
642 seem to modify the HRMT in healthy subjects, generating changes likely associated
643 with health benefits (decreasing muscle tone and stiffness while increasing
644 viscoelasticity). However, it is unclear if some muscle-technique pairs change the
645 HRMT more effectively than others (e.g., techniques using high pressure applied to
646 thicker, rather than thinner, muscles) and future studies are required to answer this

647 inquiry. More importantly, these findings may inform future research assessing the
648 effect of OMT on the HRMT in patients with MSDs.

649

REFERENCES

- 650 1. Safiri S, Kolahi AA, Cross M, Hill C, Smith E, Carson-Chahhoud K, et al. Prevalence, Deaths, and
651 Disability-Adjusted Life Years Due to Musculoskeletal Disorders for 195 Countries and Territories
652 1990-2017. *Arthritis Rheumatol.* 2021;73:702-14. doi:10.1002/art.41571.
- 653 2. Safiri S, Kolahi AA, Cross M, Carson-Chahhoud K, Almasi-Hashiani A, Kaufman J, et al. Global,
654 regional, and national burden of other musculoskeletal disorders 1990-2017: results from the Global
655 Burden of Disease Study 2017. *Rheumatology.* 2021;60:855-865.
656 doi:10.1093/rheumatology/keaa315.
- 657 3. Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, et al. Incidence trend of five common
658 musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: Results from
659 the global burden of disease study 2017. *Ann Rheum Dis.* 2020;79:1014-22.
660 doi:10.1136/annrheumdis-2020-217050.
- 661 4. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and
662 national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195
663 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study
664 2017. *Lancet.* 2018;392:1789-858. doi:10.1016/S0140-6736(18)32279-7.
- 665 5. Bornhöft L, Thorn J, Svensson M, Nordeman L, Eggertsen R, Larsson MEH. More cost-effective
666 management of patients with musculoskeletal disorders in primary care after direct triaging to
667 physiotherapists for initial assessment compared to initial general practitioner assessment. *BMC*
668 *Musculoskelet Disord.* 2019;20:1-9. doi:10.1186/s12891-019-2553-9.
- 669 6. GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019.
670 *Lancet.* 2020;396:1135-59. doi:10.1016/S0140-6736(20)31404-5.
- 671 7. Blyth FM, Briggs AM, Huckel Schneider C, Hoy DG, March LM. The global burden of
672 musculoskeletal pain - where to from here? *Am J Public Health.* 2019;109:35-40.
673 doi:10.2105/AJPH.2018.304747.
- 674 8. Lin I, Wiles L, Waller R, Goucke R, Nagree Y, Gibberd M, et al. What does best practice care for
675 musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical
676 practice guidelines: Systematic review. *Br J Sports Med.* 2020;54:79-86. doi:10.1136/bjsports-2018-
677 099878.
- 678 9. Babatunde OO, Jordan JL, Van Der Windt DA, Hill JC, Foster NE, Protheroe J. Effective
679 treatment options for musculoskeletal pain in primary care: A systematic overview of current
680 evidence. *PLoS One.* 2017;12:e0178621. doi:10.1371/journal.pone.0178621.

- 681 10. Kløjgaard ME, Manniche C, Pedersen LB, Bech M, Søgaard R. Patient preferences for treatment
 682 of low back pain - A discrete choice experiment. *Value Heal.* 2014;17:390-6.
 683 doi:10.1016/j.jval.2014.01.005.
- 684 11. Goertz CM, George SZ. Insurer Coverage of Nonpharmacological Treatments for Low Back Pain -
 685 Time for a Change. *JAMA Netw Open.* 2018;1:e183037.
- 686 12. Gianola S, Barger S, Del Castillo G, Corbetta D, Turolla A, Andreano A, et al. Effectiveness of
 687 treatments for acute and subacute mechanical non-specific low back pain: a systematic review with
 688 network meta-analysis. *Br J Sports Med.* 2022;56:41-50. doi:10.1136/bjsports-2020-103596.
- 689 13. Vaucher P, Macdonald RJD, Carnes D. The role of osteopathy in the Swiss primary health care
 690 system: A practice review. *BMJ Open.* 2018;8:e023770. doi:10.1136/bmjopen-2018-023770.
- 691 14. Tyreman S. Evidence, alternative facts and narrative: A personal reflection on person-centred
 692 care and the role of stories in healthcare. *Int J Osteopath Med.* 2018;28:1-3.
 693 doi:10.1016/j.ijosm.2018.04.005.
- 694 15. Fahlgren E, Nima AA, Archer T, Garcia D. Person-centered osteopathic practice: Patients'
 695 personality (body, mind, and soul) and health (ill-being and well-being). *PeerJ.* 2015;3:e1349.
 696 doi:10.7717/peerj.1349.
- 697 16. Grace S, Orrock P, Vaughan B, Blaich R, Coutts R. Understanding clinical reasoning in
 698 osteopathy: A qualitative research approach. *Chiropr Man Ther.* 2016;24:1-10. doi:10.1186/s12998-
 699 016-0087-x.
- 700 17. Lucas N. Psychosocial factors in osteopathic practice: To what extent should they be assessed?
 701 *Int J Osteopath Med.* 2005;8:49-59. doi:10.1016/j.ijosm.2005.04.002.
- 702 18. Saracutu M, Rance J, Davies H, Edwards DJ. The effects of osteopathic treatment on
 703 psychosocial factors in people with persistent pain: A systematic review. *Int J Osteopath Med.*
 704 2018;27:23-33. doi:10.1016/j.ijosm.2017.10.005.
- 705 19. Adams J, Sibbritt D, Steel A, Peng W. A workforce survey of Australian osteopathy: Analysis of a
 706 nationally-representative sample of osteopaths from the Osteopathy Research and Innovation
 707 Network (ORION) project. *BMC Health Serv Res.* 2018;18:1-7. doi:10.1186/s12913-018-3158-y.
- 708 20. Steel A, Peng W, Sibbritt D, Adams J. Introducing national osteopathy practice-based research
 709 networks in Australia and New Zealand: an overview to inform future osteopathic research. *Sci Rep.*
 710 2020;10:1-11. doi:10.1038/s41598-020-57918-7.
- 711 21. Sciomachen P, Arienti C, Bergna A, Castagna C, Consorti G, Lotti A, et al. Core competencies in
 712 osteopathy: Italian register of osteopaths proposal. *Int J Osteopath Med.* 2018;27:1-5.

- 713 doi:10.1016/j.ijosm.2018.02.001.
- 714 22. Kuchera ML. Applying osteopathic principles to formulate treatment for patients with chronic
715 pain. *J Am Osteopath Assoc.* 2007;107:28-38.
- 716 23. Alvarez G, Roura S, Cerritelli F, Esteves JE, Verbeeck J, van Dun PLS. The Spanish Osteopathic
717 Practitioners Estimates and Rates (OPERA) study: A cross-sectional survey. *PLoS One.*
718 2020;15:e0234713. doi:10.1371/journal.pone.0234713.
- 719 24. Smith D. Reflecting on new models for osteopathy - it's time for change. *Int J Osteopath Med.*
720 2019;31:15-20. doi:10.1016/j.ijosm.2018.10.001.
- 721 25. Sposato NS, Bjerså K. Osteopathic Manipulative Treatment in Surgical Care: Short Review of
722 Research Publications in Osteopathic Journals During the Period 1990 to 2017. *J Evidence-Based*
723 *Integr Med.* 2018;23:1-8. doi:10.1177/2515690X18767671.
- 724 26. Pincus T, Woodcock A, Vogel S. Returning back pain patients to work: How private
725 musculoskeletal practitioners outside the national health service perceive their role (an interview
726 study). *J Occup Rehabil.* 2010;20:322-30. doi:10.1007/s10926-009-9217-9.
- 727 27. Rehman Y, Ferguson H, Bozek A, Blair J, Allison A, Johnston R. Osteopathic manual treatment
728 for pain severity, functional improvement, and return to work in patients with chronic pain. *J Am*
729 *Osteopath Assoc.* 2020;120:888-906. doi:10.7556/jaoa.2020.128.
- 730 28. Bohlen L, Shaw R, Cerritelli F, Esteves JE. Osteopathy and Mental Health: An Embodied,
731 Predictive, and Interoceptive Framework. *Front Psychol.* 2021;12:1-22.
732 doi:10.3389/fpsyg.2021.767005.
- 733 29. Lunghi C, Consorti G, Tramontano M, Esteves JE, Cerritelli F. Perspectives on tissue adaptation
734 related to allostatic load: Scoping review and integrative hypothesis with a focus on osteopathic
735 palpation. *J Bodyw Mov Ther.* 2020;24:212-20. doi:10.1016/j.jbmt.2020.03.006.
- 736 30. Tamburella F, Piras F, Piras F, Spanò B, Tramontano M, Gili T. Cerebral perfusion changes after
737 osteopathic manipulative treatment: A randomized manual placebo-controlled trial. *Front Physiol.*
738 2019;10:1-10. doi:10.3389/fphys.2019.00403.
- 739 31. Task Force on the Low Back Pain Clinical Practice Guidelines. American Osteopathic Association
740 guidelines for osteopathic manipulative treatment (OMT) for patients with low back pain. *J Am*
741 *Osteopath Assoc.* 2016;116:536-49. doi:10.7556/jaoa.2016.107.
- 742 32. Giusti R. Glossary of Osteopathic Terminology. 3rd edition. American Association of Colleges of
743 Osteopathic Medicine; 2017. [https://www.aacom.org/docs/default-](https://www.aacom.org/docs/default-source/insideome/got2011ed.pdf)
744 [source/insideome/got2011ed.pdf](https://www.aacom.org/docs/default-source/insideome/got2011ed.pdf).

- 745 33. Ajimsha MS, Al-Mudahka NR, Al-Madzhar JA. Effectiveness of myofascial release: Systematic
746 review of randomized controlled trials. *J Bodyw Mov Ther.* 2015;19:102-12.
747 doi:10.1016/j.jbmt.2014.06.001.
- 748 34. McKenney K, Elder AS, Elder C, Hutchins A. Myofascial release as a treatment for orthopaedic
749 conditions: A systematic review. *J Athl Train.* 2013;48:522-7. doi:10.4085/1062-6050-48.3.17.
- 750 35. Beardsley C, Škarabot J. Effects of self-myofascial release: A systematic review. *J Bodyw Mov*
751 *Ther.* 2015;19:747-58. doi:10.1016/j.jbmt.2015.08.007.
- 752 36. Krause F, Wilke J, Niederer D, Vogt L, Banzer W. Acute effects of foam rolling on passive tissue
753 stiffness and fascial sliding: Study protocol for a randomized controlled trial. *Trials.* 2017;18:1-6.
- 754 37. Zein-Hammoud M, Standley PR. Modeled osteopathic manipulative treatments: A review of their
755 in vitro effects on fibroblast tissue preparations. *J Am Osteopath Assoc.* 2015;115:490-502.
756 doi:10.7556/jaoa.2015.103.
- 757 38. Laimi K, Mäkilä A, Bärlund E, Katajapuu N, Oksanen A, Seikkula V, et al. Effectiveness of
758 myofascial release in treatment of chronic musculoskeletal pain: a systematic review. *Clin Rehabil.*
759 2018;32:440-50. doi:10.1177/0269215517732820.
- 760 39. Wu Z, Wang Y, Ye X, Chen Z, Zhou R, Ye Z, et al. Myofascial Release for Chronic Low Back Pain:
761 A Systematic Review and Meta-Analysis. *Front Med.* 2021;8:1-14. doi:10.3389/fmed.2021.697986.
- 762 40. Chen Z, Wu J, Wang X, Wu J, Ren Z. The effects of myofascial release technique for patients
763 with low back pain: A systematic review and meta-analysis. *Complement Ther Med.*
764 2021;59:102737. doi:10.1016/j.ctim.2021.102737.
- 765 41. Franke H, Fryer G, Ostelo RWJG, Kamper SJ. Muscle energy technique for non-specific low-back
766 pain. A Cochrane systematic review. *Int J Osteopath Med.* 2016;20:41-52.
767 doi:10.1016/j.ijosm.2016.01.002.
- 768 42. Fryer G. Muscle energy technique: An evidence-informed approach. *Int J Osteopath Med.*
769 2011;14:3-9. doi:10.1016/j.ijosm.2010.04.004.
- 770 43. Thomas E, Cavallaro AR, Mani D, Bianco A, Palma A. The efficacy of muscle energy techniques
771 in symptomatic and asymptomatic subjects: A systematic review. *Chiropr Man Ther.* 2019;27:1-18.
772 doi:10.1186/s12998-019-0258-7.
- 773 44. Koren Y, Kalichman L. Deep tissue massage: What are we talking about? *J Bodyw Mov Ther.*
774 2018;22:247-51. doi:10.1016/j.jbmt.2017.05.006.
- 775 45. El-Hafez HM, Hamdy HA, Takla MK, Ahmed SEB, Genedy AF, Abd EL-Azeim ASS. Instrument-
776 assisted soft tissue mobilisation versus stripping massage for upper trapezius myofascial trigger

- 777 points. *J Taibah Univ Med Sci.* 2020;15:87-93. doi:10.1016/j.jtumed.2020.01.006.
- 778 46. Bell J. Massage therapy helps to increase range of motion, decrease pain and assist in healing a
779 client with low back pain and sciatica symptoms. *J Bodyw Mov Ther.* 2008;12:281-9.
780 doi:10.1016/j.jbmt.2008.01.006.
- 781 47. Waters-Banker C, Dupont-Versteegden EE, Kitzman PH, Butterfield TA. Investigating the
782 mechanisms of massage efficacy: The role of mechanical immunomodulation. *J Athl Train.*
783 2014;49:266-73. doi:10.4085/1062-6050-49.2.25.
- 784 48. Loghmani MT, Whitted M. Soft Tissue Manipulation: A Powerful Form of Mechanotherapy. *J*
785 *Physiother Phys Rehabil.* 2016;1:1-6. doi:10.4172/2573-0312.1000122.
- 786 49. Weerapong P, Hume PA, Kolt GS. The Mechanisms of Massage and Effects on Performance,
787 Muscle Recovery and Injury Prevention. *Sport Med.* 2005;35:235-56. doi:10.2165/00007256-
788 200535030-00004.
- 789 50. Furlan AD, Giraldo M, Baskwill A, Irvin E, Imamura M. Massage for low-back pain. *Cochrane*
790 *Database Syst Rev.* 2015;2015:CD001929. doi:10.1002/14651858.CD001929.pub3.
- 791 51. Furlan AD, Brosseau L, Imamura M, Irvin E. Massage for low-back pain: A systematic review
792 within the framework of the Cochrane Collaboration Back Review Group. *Spine.* 2002;27:1896-910.
793 doi:10.1097/00007632-200209010-00017.
- 794 52. Furlan AD, Imamura M, Dryden T, Irvin E. Massage for low-back pain: An updated systematic
795 review within the framework of the Cochrane Back Review Group. *Spine.* 2009;34:1669-84.
796 doi:10.1097/BRS.0b013e3181ad7bd6.
- 797 53. Johnson JC, Degenhardt BF. Who uses osteopathic manipulative treatment? A prospective,
798 observational study conducted by DO-Touch.NET. *J Am Osteopath Assoc.* 2019;119:802-12.
799 doi:10.7556/jaoa.2019.133.
- 800 54. Rubinstein SM, De Zoete A, Van Middelkoop M, Assendelft WJJ, De Boer MR, Van Tulder MW.
801 Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain:
802 Systematic review and meta-analysis of randomised controlled trials. *BMJ.* 2019;364:1-15.
803 doi:10.1136/bmj.l689.
- 804 55. Switters JM, Podar S, Perraton L, Machotka Z. Is visceral manipulation beneficial for patients
805 with low back pain? A systematic review of the literature. *Int J Osteopath Med.* 2019;33:16-23.
806 doi:10.1016/j.ijosm.2019.09.002.
- 807 56. Verhaeghe N, Schepers J, van Dun P, Annemans L. Osteopathic care for spinal complaints: A
808 systematic literature review. *PLoS One.* 2018;13:e0206284. doi:10.1371/journal.pone.0206284.

- 809 57. Franke H, Franke JD, Fryer G. Osteopathic manipulative treatment for chronic nonspecific neck
 810 pain: A systematic review and meta-analysis. *Int J Osteopath Med.* 2015;18:255-67.
 811 doi:10.1016/j.ijosm.2015.05.003.
- 812 58. Dal Farra F, Risio RG, Vismara L, Bergna A. Effectiveness of osteopathic interventions in chronic
 813 non-specific low back pain: A systematic review and meta-analysis. *Complement Ther Med.*
 814 2021;56:102616. doi:10.1016/j.ctim.2020.102616.
- 815 59. Franke H, Franke JD, Fryer G. Osteopathic manipulative treatment for nonspecific low back
 816 pain: A systematic review and meta-analysis. *BMC Musculoskelet Disord.* 2014;15:1-18.
 817 doi:10.1186/1471-2474-15-286.
- 818 60. Licciardone JC, Brimhall AK, King LN. Osteopathic manipulative treatment for low back pain: A
 819 systematic review and meta-analysis of randomized controlled trials. *BMC Musculoskelet Disord.*
 820 2005;6:1-12. doi:10.1186/1471-2474-6-43.
- 821 61. Franke H, Franke J-D, Belz S, Fryer G. Osteopathic manipulative treatment for low back and
 822 pelvic girdle pain during and after pregnancy: A systematic review and meta-analysis. *J Bodyw Mov*
 823 *Ther.* 2017;21:752-62. doi:10.1016/j.jbmt.2017.05.014.
- 824 62. Licciardone JC, Gatchel RJ. Osteopathic medical care with and without osteopathic
 825 manipulative treatment in patients with chronic low back pain: A pain registry-based study. *J Am*
 826 *Osteopath Assoc.* 2020;120:64-73. doi:10.7556/jaoa.2020.016.
- 827 63. Franzetti M, Dries E, Stevens B, Berkowitz L, Yao SC. Support for osteopathic manipulative
 828 treatment inclusion in chronic pain management guidelines: a narrative review. *J Osteopath Med.*
 829 2021;121:307-17. doi:10.1515/jom-2019-0284.
- 830 64. Verhaeghe N, Schepers J, van Dun P, Annemans L. Osteopathic care for low back pain and neck
 831 pain: A cost-utility analysis. *Complement Ther Med.* 2018;40:207-13.
 832 doi:10.1016/j.ctim.2018.06.001.
- 833 65. Nguyen C, Boutron I, Zegarra-Parodi R, Baron G, Alami S, Sanchez K, et al. Effect of
 834 Osteopathic Manipulative Treatment vs Sham Treatment on Activity Limitations in Patients With
 835 Nonspecific Subacute and Chronic Low Back Pain A Randomized Clinical Trial. *JAMA Intern Med.*
 836 2021;181:620-30. doi:10.1001/jamainternmed.2021.0005.
- 837 66. Orrock PJ, Myers SP. Osteopathic intervention in chronic non-specific low back pain: A
 838 systematic review. *BMC Musculoskelet Disord.* 2013;14:1-7. doi:10.1186/1471-2474-14-129.
- 839 67. Posadzki P, Ernst E. Osteopathy for musculoskeletal pain patients: A systematic review of
 840 randomized controlled trials. *Clin Rheumatol.* 2011;30:285-91. doi:10.1007/s10067-010-1600-6.

- 841 68. Lewis R, Gómez Álvarez CB, Rayman M, Lanham-New S, Woolf A, Mobasheri A. Strategies for
 842 optimising musculoskeletal health in the 21st century. *BMC Musculoskelet Disord*. 2019;20:1-15.
 843 doi:10.1186/s12891-019-2510-7.
- 844 69. Dunn M, Rushton AB, Mistry J, Soundy A, Heneghan NR. Which biopsychosocial factors are
 845 associated with the development of chronic musculoskeletal pain? Protocol for an umbrella review
 846 of systematic reviews. *BMJ Open*. 2021;11:e053941. doi:10.1136/bmjopen-2021-053941.
- 847 70. Sampath KK, Darlow B, Tumilty S, Shillito W, Hanses M, Devan H, et al. Barriers and facilitators
 848 experienced by osteopaths in implementing a biopsychosocial (BPS) framework of care when
 849 managing people with musculoskeletal pain - a mixed methods systematic review. *BMC Health Serv*
 850 *Res*. 2021;21:1-15. doi:10.1186/s12913-021-06720-w.
- 851 71. Hu X, Lei D, Li L, Leng Y, Yu Q, Wei X, et al. Quantifying paraspinal muscle tone and stiffness in
 852 young adults with chronic low back pain: a reliability study. *Sci Rep*. 2018;8:1-10.
 853 doi:10.1038/s41598-018-32418-x.
- 854 72. Lo WLA, Yu Q, Mao Y, Li W, Hu C, Li L. Lumbar muscles biomechanical characteristics in young
 855 people with chronic spinal pain. *BMC Musculoskelet Disord*. 2019;20:1-9. doi:10.1186/s12891-019-
 856 2935-z.
- 857 73. Chin J, Qiu W, Lomiguen CM, Volokitin M. Osteopathic Manipulative Treatment in Tension
 858 Headaches. *Cureus*. 2020;12:e12040. doi:10.7759/cureus.12040.
- 859 74. Tramontano M, Cerritelli F, Piras F, Spanò B, Tamburella F, Piras F, et al. Brain Connectivity
 860 Changes after Osteopathic Manipulative Treatment: A Randomized Manual Placebo-Controlled Trial.
 861 *Brain Sci*. 2020;10:1-15. doi:10.3390/brainsci10120969.
- 862 75. Goldfinger MS, Moriarty S, DelPlato K, Yao SC, Leder A, Mancini JD. An osteopathic, non
 863 pharmacologic approach to parkinson's disease, restless leg syndrome & essential tremor.
 864 *Osteopath Fam Physician*. 2017;9:30-8. doi:10.1016/ofp.v9i6.525.
- 865 76. Collebrusco L, Fabri S, Furfaro A, Tanini I, Lombardini R, Rizza A, et al. Osteopathy and
 866 Emergency: A Model of Osteopathic Treatment Aimed at Managing the Post-Traumatic Stress - Brief
 867 and Useful Guide - Part 2. *Health*. 2018;10:1597-608. doi:10.4236/health.2018.1011120.
- 868 77. Nair K, Masi AT, Andonian BJ, Barry AJ, Coates BA, Dougherty J, et al. Stiffness of resting
 869 lumbar myofascia in healthy young subjects quantified using a handheld myotonometer and
 870 concurrently with surface electromyography monitoring. *J Bodyw Mov Ther*. 2016;20:388-96.
 871 doi:10.1016/j.jbmt.2015.12.005.
- 872 78. Knutson GA, Owens EF. Active and passive characteristics of muscle tone and their relationship
 873 to models of subluxation/joint dysfunction: Part I. *J Can Chiropr Assoc*. 2003;47:168-79.

- 874 79. Masi AT, Hannon JC. Human resting muscle tone (HRMT): Narrative introduction and modern
875 concepts. *J Bodyw Mov Ther.* 2008;12:320-32. doi:10.1016/j.jbmt.2008.05.007.
- 876 80. Mense S, Masi AT. Increased Muscle Tone as a Cause of Muscle Pain. In: *Muscle Pain:
877 Understanding the Mechanisms.* 2010. p. 207-49. doi:10.1007/978-3-540-85021-2.
- 878 81. Schoenrock B, Zander V, Dern S, Limper U, Mulder E, Verakšič A, et al. Bed rest, exercise
879 countermeasure and reconditioning effects on the human resting muscle tone system. *Front
880 Physiol.* 2018;9:1-20. doi:10.3389/fphys.2018.00810.
- 881 82. Boesler D, Warner M, Alpers A, Finnerty EP, Kilmore MA. Efficacy of high-velocity low-amplitude
882 manipulative technique in subjects with low-back pain during menstrual cramping. *J Am Osteopath
883 Assoc.* 1993;93:203-14. doi:10.7556/jaoa.1993.93.2.203.
- 884 83. Korotkov K, Shelkov O, Shevtsov A, Mohov D, Paoletti S, Mirosnichenko D, et al. Stress reduction
885 with osteopathy assessed with GDV electrophotonic imaging: Effects of osteopathy treatment. *J
886 Altern Complement Med.* 2012;18:251-7. doi:10.1089/acm.2010.0853.
- 887 84. Rajaii RM, Cox GJ, Schneider RP. Role of osteopathic manipulative treatment in the
888 management of stiff person syndrome. *J Am Osteopath Assoc.* 2015;115:394-8.
889 doi:10.7556/jaoa.2015.081.
- 890 85. Alexander N, Rastelli A, Webb T, Rajendran D. The validity of lumbo-pelvic landmark palpation
891 by manual practitioners: a systematic review. *Int J Osteopath Med.* 2021;39:10-20.
892 doi:10.1016/j.ijosm.2020.10.008.
- 893 86. Basile F, Petracca M, Scionti R. Diagnostic reliability of osteopathic tests: A systematic review.
894 *Int J Osteopath Med.* 2017;25:21-9. doi:10.1016/j.ijosm.2017.03.004.
- 895 87. May S, Littlewood C, Bishop A. Reliability of procedures used in the physical examination of
896 non-specific low back pain: A systematic review. *Aust J Physiother.* 2006;52:91-102.
897 doi:10.1016/S0004-9514(06)70044-7.
- 898 88. Najm WI, Seffinger MA, Mishra SI, Dickerson VM, Adams A, Reinsch S, et al. Content validity of
899 manual spinal palpatory exams - A systematic review. *BMC Complement Altern Med.* 2003;3:1-14.
- 900 89. Póvoa LC, Ferreira APA, Silva JG. Validation of palpatory methods for evaluating anatomical
901 bone landmarks of the cervical spine: A systematic review. *J Manipulative Physiol Ther.*
902 2015;38:302-10. doi:10.1016/j.jmpt.2015.04.002.
- 903 90. Cooperstein R, Hickey M. The reliability of palpating the posterior superior iliac spine: A
904 systematic review. *J Can Chiropr Assoc.* 2016;60:36-46.
- 905 91. Stochkendahl MJ, Christensen HW, Hartvigsen J, Vach W, Haas M, Hestbaek L, et al. Manual

- 906 examination of the spine: a systematic critical literature review of reproducibility. *J Manipulative*
907 *Physiol Ther.* 2006;29:475-85. doi:10.1016/j.jmpt.2006.06.011.
- 908 92. Nolet PS, Yu H, Côté P, Meyer AL, Kristman VL, Sutton D, et al. Reliability and validity of
909 manual palpation for the assessment of patients with low back pain: a systematic and critical
910 review. *Chiropr Man Ther.* 2021;29:1-20.
- 911 93. Chen G, Wu J, Chen G, Lu Y, Ren W, Xu W, et al. Reliability of a portable device for quantifying
912 tone and stiffness of quadriceps femoris and patellar tendon at different knee flexion angles. *PLoS*
913 *One.* 2019;14:e0220521. doi:10.1371/journal.pone.0220521.
- 914 94. Hsu JJ, Stasiak AM, Ranganathan K, Adelman EE, Janis JE, Cederna PS, et al. Morphometric
915 Evaluation of the Frontal Migraine Trigger Site. *Plast Reconstr Surg.* 2018;141:726-32.
916 doi:10.1097/PRS.0000000000004296.
- 917 95. Durão APR, Morosolli A, Brown J, Jacobs R. Masseter muscle measurement performed by
918 ultrasound: A systematic review. *Dentomaxillofacial Radiol.* 2017;46:20170052.
919 doi:10.1259/dmfr.20170052.
- 920 96. Salavati M, Akhbari B, Ebrahimi Takamjani I, Ezzati K, Haghhighatkah H. Reliability of the Upper
921 Trapezius Muscle and Fascia Thickness and Strain Ratio Measures by Ultrasonography and
922 Sonoelastography in Participants With Myofascial Pain Syndrome. *J Chiropr Med.* 2017;16:316-23.
923 doi:10.1016/j.jcm.2017.06.003.
- 924 97. Pinar Y, Govsa F, Ozer MA, Ertam I. Anatomocosmetic implication rules of the corrugator
925 supercilii muscle for youthful eye appearance. *Surg Radiol Anat.* 2016;38:1045-51.
926 doi:10.1007/s00276-016-1666-1.
- 927 98. Azaroual MF, Fikri M, Abouqal R, Benyahya H, Zaoui F. Relationship between dimensions of
928 muscles of mastication (masseter and lateral pterygoid) and skeletal dimensions: Study of 40 cases.
929 *Int Orthod.* 2014;12:111-24. doi:10.1016/j.ortho.2013.09.001.
- 930 99. Tiwari R, Snow GB. Role of myocutaneous flaps in reconstruction of the head and neck. *J*
931 *Laryngol Otol.* 1983;97:441-58. doi:10.1017/s0022215100094378.
- 932 100. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated
933 guidelines for reporting parallel group randomised trials. *BMJ.* 2010;340:698-702.
934 doi:10.1136/bmj.c332.
- 935 101. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010
936 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials.
937 *BMJ.* 2010;340:1-28. doi:10.1136/bmj.c869.

- 938 102. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and Reporting of Factorial Trials: A
 939 Systematic Review. *JAMA*. 2003;289:2545-53. doi:10.1001/jama.289.19.2545.
- 940 103. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles
 941 for Medical Research Involving Human Subjects. *JAMA*. 2013;310:2191-4.
 942 doi:10.1001/jama.2013.281053.
- 943 104. Létocart AJ, Mabesoone F, Charleux F, Couppé C, Svensson RB, Marin F, et al. Muscles
 944 adaptation to aging and training: architectural changes - a randomised trial. *BMC Geriatr*.
 945 2021;21:1-18. doi:10.1186/s12877-020-02000-0.
- 946 105. Agyapong-Badu S, Warner M, Samuel D, Stokes M. Measurement of ageing effects on muscle
 947 tone and mechanical properties of rectus femoris and biceps brachii in healthy males and females
 948 using a novel hand-held myometric device. *Arch Gerontol Geriatr*. 2016;62:59-67.
 949 doi:10.1016/j.archger.2015.09.011.
- 950 106. Ghaoui R, Clarke N, Hollingworth P, Needham M. Muscle disorders: The latest investigations.
 951 *Intern Med J*. 2013;43:970-8. doi:10.1111/imj.12234.
- 952 107. Tozzi P. A unifying neuro-fasciagenic model of somatic dysfunction - Underlying mechanisms
 953 and treatment - Part II. *J Bodyw Mov Ther*. 2015;19:526-43. doi:10.1016/j.jbmt.2015.03.002.
- 954 108. Minasny B. Understanding the process of fascial unwinding. *Int J Ther Massage Bodyw*.
 955 2009;2:10-7. doi:10.3822/ijtmb.v2i3.43.
- 956 109. Moore SD, Laudner KG, McLoda TA, Shaffer MA. The immediate effects of muscle energy
 957 technique on posterior shoulder tightness: A randomized controlled trial. *J Orthop Sports Phys*
 958 *Ther*. 2011;41:400-7. doi:10.2519/jospt.2011.3292.
- 959 110. Harrer G. The Fascial Distortion Model originated by Stephen P. Typaldos. In: Liem T, Tozzi P,
 960 Chila A, editors. *Fascia in the Osteopathic Field*. Edinburgh: Handspring Publishing; 2017. p. 359-68.
- 961 111. Myoton. MyotonPRO User Manual. 2013.
 962 https://www.myoton.com/UserFiles/Updates/MyotonPRO_User_Manual.pdf.
- 963 112. Garcia-Bernal MI, Heredia-Rizo AM, Gonzalez-Garcia P, Cortés-Vega MD, Casuso-Holgado MJ.
 964 Validity and reliability of myotonometry for assessing muscle viscoelastic properties in patients with
 965 stroke: a systematic review and meta-analysis. *Sci Rep*. 2021;11:1-12. doi:10.1038/s41598-021-
 966 84656-1.
- 967 113. Roch M, Morin M, Gaudreault N. The MyotonPRO: A reliable tool for quantifying the viscoelastic
 968 properties of a trigger point on the infraspinatus in non-traumatic chronic shoulder pain. *J Bodyw*
 969 *Mov Ther*. 2020;24:379-85. doi:10.1016/j.jbmt.2020.05.002.

- 970 114. Kim KR, Shin HS, Lee SB, Hwang HS, Shin HJ. Effects of Negative Pressure Soft Tissue Therapy
 971 to Ankle Plantar Flexor on Muscle Tone, Muscle Stiffness, and Balance Ability in Patients with
 972 Stroke. *J Int Acad Phys Ther Res.* 2018;9:1468-74. doi:10.20540/JIAPTR.2018.9.2.1468.
- 973 115. Wang JS. Therapeutic effects of massage and electrotherapy on muscle tone, stiffness and
 974 muscle contraction following gastrocnemius muscle fatigue. *J Phys Ther Sci.* 2017;29:144-7.
 975 doi:10.1589/jpts.29.144.
- 976 116. Kocur P, Wilski M, Lewandowski J, Łochyński D. Female Office Workers With Moderate Neck
 977 Pain Have Increased Anterior Positioning of the Cervical Spine and Stiffness of Upper Trapezius
 978 Myofascial Tissue in Sitting Posture. *PM&R.* 2019;11:476-82. doi:10.1016/j.pmrj.2018.07.002.
- 979 117. Kisilewicz A, Madeleine P, Ignasiak Z, Cizek B, Kawczynski A, Larsen RG. Eccentric Exercise
 980 Reduces Upper Trapezius Muscle Stiffness Assessed by Shear Wave Elastography and Myotonometry.
 981 *Front Bioeng Biotechnol.* 2020;8:1-9. doi:10.3389/fbioe.2020.00928.
- 982 118. Taş S, Yaşar Ü, Kaynak BA. Interrater and Intrarater Reliability of a Handheld Myotonometer in
 983 Measuring Mechanical Properties of the Neck and Orofacial Muscles. *J Manipulative Physiol Ther.*
 984 2021;44:42-8. doi:10.1016/j.jmpt.2020.08.002.
- 985 119. Kisilewicz A, Janusiak M, Szafraniec R, Smoter M, Cizek B, Madeleine P, et al. Changes in
 986 Muscle Stiffness of the Trapezius Muscle after Application of Ischemic Compression into Myofascial
 987 Trigger Points in Professional Basketball Players. *J Hum Kinet.* 2018;64:35-45. doi:10.2478/hukin-
 988 2018-0043.
- 989 120. Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. Anatomy of the corrugator supercilii
 990 muscle: Part I. Corrugator topography. *Plast Reconstr Surg.* 2007;120:1647-53.
 991 doi:10.1097/01.prs.0000282725.61640.e1.
- 992 121. Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. The anatomy of the corrugator
 993 supercilii muscle: Part II. Supraorbital nerve branching patterns. *Plast Reconstr Surg.* 2008;121:233-
 994 40. doi:10.1097/01.prs.0000299260.04932.38.
- 995 122. Lee JY, Kim JN, Yoo JY, Hu KS, Kim HJ, Song WC, et al. Topographic anatomy of the masseter
 996 muscle focusing on the tendinous digitation. *Clin Anat.* 2012;25:889-92. doi:10.1002/ca.22024.
- 997 123. Kitai N, Fujii Y, Murakami S, Furukawa S, Kreiborg S, Takada K. Human masticatory muscle
 998 volume and zygomatico-mandibular form in adults with mandibular prognathism. *J Dent Res.*
 999 2002;81:752-6. doi:10.1177/154405910208101106.
- 1000 124. Kawczyńska A, Mroczek D, Andersen RE, Stefaniak T, Arendt-Nielsen L, Madeleine P. Trapezius
 1001 viscoelastic properties are heterogeneously affected by eccentric exercise. *J Sci Med Sport.*
 1002 2018;21:864-9. doi:https://doi.org/10.1016/j.jsams.2018.01.005.

- 1003 125. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical power analysis
1004 program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 2007;39:175-91.
1005 doi:10.3758/bf03193146.
- 1006 126. Heinrich-Heine-Universität. G*Power: Statistical Power Analyses for Windows and Mac. 2015.
1007 <http://www.gpower.hhu.de/>.
- 1008 127. Dong C, Wedel M. BANOVA: An R Package for Hierarchical Bayesian ANOVA. *J Stat Softw*.
1009 2017;81. doi:10.18637/jss.v081.i09.
- 1010 128. Westfall PH, Johnson WO, Utts JM. A Bayesian perspective on the Bonferroni adjustment.
1011 *Biometrika*. 1997;84:419-27. doi:10.1093/biomet/84.2.419.
- 1012 129. Kang H. The prevention and handling of the missing data. *Korean J Anesthesiol*. 2013;64:402-
1013 6. doi:10.4097/kjae.2013.64.5.402.
- 1014 130. Coates B, Barry A, Dougherty J, Schaefer E, Kelly J, Aldag J, et al. Quantifying intrinsic
1015 properties of resting lumbar muscle in healthy subjects using a handheld myometer. In: *Proceedings*
1016 *of the 40th Annual Northeast Bioengineering Conference by IEEE Xplore*. Boston; 2014.
- 1017 131. Ingber DE. Tensegrity and mechanotransduction. *J Bodyw Mov Ther*. 2008;12:198-200.
1018 doi:10.1016/j.jbmt.2008.04.038.
- 1019 132. Albin SR, Koppenhaver SL, Bailey B, Blommel H, Fenter B, Lowrimore C, et al. The effect of
1020 manual therapy on gastrocnemius muscle stiffness in healthy individuals. *Foot*. 2019;38:70-5.
1021 doi:10.1016/j.foot.2019.01.006.
- 1022 133. Kisilewicz A, Urbaniak M, Kawczyński A. Effect of muscle energy technique on calf muscle
1023 stiffness increased after eccentric exercise in athletes. *J Kinesiol Exerc Sci*. 2018;28:21-9.
1024 doi:10.5604/01.3001.0012.7985.
- 1025 134. Chang TT, Li Z, Zhu YC, Wang XQ, Zhang ZJ. Effects of Self-Myofascial Release Using a Foam
1026 Roller on the Stiffness of the Gastrocnemius-Achilles Tendon Complex and Ankle Dorsiflexion Range
1027 of Motion. *Front Physiol*. 2021;12:1-9. doi:10.3389/fphys.2021.718827.
- 1028 135. Pérez-Bellmunt A, Labata-Lezaun N, Llorda-Almuzara L, Rodríguez-Sanz J, González-Rueda V,
1029 Bueno-Gracia E, et al. Effects of a massage protocol in tensiomyographic and myotonometric
1030 properties. *Int J Environ Res Public Health*. 2021;18:1-9. doi:10.3390/ijerph18083891.
- 1031 136. Gordon CM, Andrasik F, Schleip R, Birbaumer N, Rea M. Myofascial triggerpoint release (MTR)
1032 for treating chronic shoulder pain: A novel approach. *J Bodyw Mov Ther*. 2016;20:614-22.
1033 doi:10.1016/j.jbmt.2016.01.009.
- 1034 137. Park SJ, Kim SH, Kim SH. Effects of thoracic mobilization and extension exercise on thoracic

- 1035 alignment and shoulder function in patients with subacromial impingement syndrome: A
 1036 randomized controlled pilot study. *Healthcare*. 2020;8:1-11. doi:10.3390/healthcare8030316.
- 1037 138. Alcaraz-Clariana S, García-Luque L, Garrido-Castro JL, Carmona-Pérez C, Rodrigues-de-Souza
 1038 DP, Fernández-de-las-Peñas C, et al. Influence of Spinal Movements Associated with Physical
 1039 Evaluation on Muscle Mechanical Properties of the Lumbar Paraspinal in Subjects with Acute Low
 1040 Back Pain. *Diagnostics*. 2022;12:1-10.
- 1041 139. Hamilton RI, Garden CLP, Brown SJ. Immediate effect of a spinal mobilisation intervention on
 1042 muscle stiffness, tone and elasticity in subjects with lower back pain - A randomized cross-over
 1043 trial. *J Bodyw Mov Ther*. 2022;29:60-7. doi:10.1016/j.jbmt.2021.09.032.
- 1044 140. Taş S, Salkın Y. An investigation of the sex-related differences in the stiffness of the Achilles
 1045 tendon and gastrocnemius muscle: Inter-observer reliability and inter-day repeatability and the
 1046 effect of ankle joint motion. *Foot*. 2019;41:44-50. doi:10.1016/j.foot.2019.09.003.
- 1047 141. Ilahi S, Masi AT, White A, Devos A, Henderson J, Nair K. Quantified biomechanical properties
 1048 of lower lumbar myofascia in younger adults with chronic idiopathic low back pain and matched
 1049 healthy controls. *Clin Biomech*. 2020;73:78-85. doi:10.1016/j.clinbiomech.2019.12.026.
- 1050 142. Wu Z, Wang Y, Ye Z, Guan Y, Ye X, Chen Z, et al. Effects of Age and Sex on Properties of
 1051 Lumbar Erector Spinae in Healthy People: Preliminary Results From a Pilot Study. *Front Physiol*.
 1052 2021;12:1-10. doi:10.3389/fphys.2021.718068.
- 1053 143. Ng JKF, Richardson CA, Kippers V, Parnianpour M. Relationship between muscle fiber
 1054 composition and functional capacity of back muscles in healthy subjects and patients with back
 1055 pain. *J Orthop Sports Phys Ther*. 1998;27:389-402. doi:10.2519/jospt.1998.27.6.389.
- 1056 144. Couper DJ, Hosking JD, Cisler RA, Gastfriend DR, Kivlahan DR. Factorial designs in clinical
 1057 trials: Options for combination treatment studies. *J Stud Alcohol Drugs*. 2005;15:24-32.
 1058 doi:10.15288/jsas.2005.s15.24.
- 1059 145. Simmons JP, Nelson LD, Simonsohn U. False-positive psychology: Undisclosed flexibility in data
 1060 collection and analysis allows presenting anything as significant. *Psychol Sci*. 2011;22:1359-66.
 1061 doi:10.1177/0956797611417632.
- 1062 146. Bizzini M, Mannion AF. Reliability of a new, hand-held device for assessing skeletal muscle
 1063 stiffness. *Clin Biomech*. 2003;18:459-61. doi:10.1016/S0268-0033(03)00042-1.
- 1064 147. Kerins CM, Moore SD, Butterfield TA, McKeon PO, Uhl TL. Reliability of the myotonometer for
 1065 assessment of posterior shoulder tightness. *Int J Sports Phys Ther*. 2013;8:248-55.
- 1066 148. Lorenc ZP, Smith S, Nestor M, Nelson D, Moradi A. Understanding the functional anatomy of

- 1067 the frontalis and glabellar complex for optimal aesthetic botulinum toxin type A therapy. *Aesthetic*
1068 *Plast Surg.* 2013;37:975-83. doi:10.1007/s00266-013-0178-1.
- 1069 149. Macdonald MR, Spiegel JH, Raven RB, Kabaker SS, Maas CS. An anatomical approach to
1070 glabellar rhytids. *JAMA Otolaryngol - Head Neck Surg.* 1998;124:1315-20.
1071 doi:10.1001/archotol.124.12.1315.
- 1072 150. Weir A, Veger SAS, Van De Sande HBA, Bakker EWP, De Jonge S, Tol JL. A manual therapy
1073 technique for chronic adductor-related groin pain in athletes: A case series. *Scand J Med Sci Sport.*
1074 2009;19:616-20. doi:10.1111/j.1600-0838.2008.00841.x.
- 1075 151. Simons DG, Mense S. Understanding and measurement of muscle tone as related to clinical
1076 muscle pain. *Pain.* 1998;75:1-17. doi:10.1016/S0304-3959(97)00102-4.
- 1077 152. Standley PR. My personal journey that led to the crossroads of interdisciplinary manual
1078 medicine research: Serendipitous opportunities afforded a basic scientist. *J Am Osteopath Assoc.*
1079 2013;113:179-83. doi:10.7556/jaoa.2013.113.2.179.
- 1080 153. Standley PR. Towards a Rosetta Stone of manual therapeutic methodology. *J Bodyw Mov Ther.*
1081 2014;18:586-7. doi:10.1016/j.jbmt.2014.06.004.
- 1082 154. Alcaraz-Clariana S, García-Luque L, Garrido-Castro JL, Fernández-de-las-Peñas C, Carmona-
1083 Pérez C, Rodrigues-de-Souza DP, et al. Paravertebral Muscle Mechanical Properties and Spinal
1084 Range of Motion in Patients with Acute Neck or Low Back Pain: A Case-Control Study. *Diagnostics.*
1085 2021;11:1-21. doi:10.3390/diagnostics11020352.
- 1086 155. Wu Z, Zhu Y, Xu W, Liang J, Guan Y, Xu X. Analysis of Biomechanical Properties of the Lumbar
1087 Extensor Myofascia in Elderly Patients with Chronic Low Back Pain and That in Healthy People.
1088 *Biomed Res Int.* 2020;2020:7649157. doi:10.1155/2020/7649157.
- 1089 156. Andonian BJ, Masi AT, Aldag JC, Barry AJ, Coates BA, Emrich K, et al. Greater Resting Lumbar
1090 Extensor Myofascial Stiffness in Younger Ankylosing Spondylitis Patients Than Age-Comparable
1091 Healthy Volunteers Quantified by Myotonometry. *Arch Phys Med Rehabil.* 2015;96:2041-7.
1092 doi:10.1016/j.apmr.2015.07.014.
- 1093 157. Garrido-Castro JL, Aranda-Valera IC, Peña-Amaro J, Martínez-Galisteo A, González-Navas C,
1094 Rodrigues-De-Souza DP, et al. Mechanical properties of lumbar and cervical paravertebral muscles
1095 in patients with axial spondyloarthritis: A case-control study. *Diagnostics.* 2021;11:1-12.
1096 doi:10.3390/diagnostics11091662.
- 1097 158. White A, Abbott H, Masi AT, Henderson J, Nair K. Biomechanical properties of low back
1098 myofascial tissue in younger adult ankylosing spondylitis patients and matched healthy control
1099 subjects. *Clin Biomech.* 2018;57:67-73. doi:10.1016/j.clinbiomech.2018.06.006.

1100 159. Lederer AK, Maly C, Weinert T, Huber R. Tissue Stiffness is Not Related to Pain Experience: An
1101 Individually Controlled Study in Patients with Chronic Neck and Back Pain. Evidence-Based
1102 Complement Altern Med. 2019;2019:1907168. doi:10.1155/2019/1907168.

1103

DECLARATIONS

1104

1105 **Abbreviations:**

1106 **MRT:** Myofascial Release Technique; **MET:** Muscle Energy Technique; **STT:** Soft
1107 Tissue Technique; **CS:** Corrugator Supercilii Muscle; **SM:** Superficial Masseter Muscle;
1108 **UT:** Upper Trapezius Muscle; **F:** Oscillation Frequency; **S:** Dynamic Stiffness; **D:**
1109 Logarithmic Decrement; **R:** Mechanical Stress Relaxation Time; **C:** Ratio of
1110 Deformation and Relaxation Time; **MSDs:** Musculoskeletal Disorders; **HRMT:** Human
1111 Resting Muscle Tone; **OMT:** Osteopathic Manipulative Treatment; **EMG:**
1112 Electromyography; **MPs:** Measurement Points.

1113 **Acknowledgements:**

1114 We like to express our gratitude to (i) the students and staff of the Osteopathie
1115 Schule Deutschland for their participation and assistance during the trial; (ii)
1116 Alexander Karner, MSc, Christian Selzle, MSc, Stephan Rohde, MSc, and Charline
1117 Krohn for providing intellectual, organizational, and spatial support; (iii) Ass. Prof.
1118 Jan Porthun, MMSc for helpful discussions about the study design and statistics;
1119 and (iv) Dr. Christine Lohr, MSc, and Marius Dickmann, MSc for proofreading the
1120 manuscript and providing thoughtful comments.

1121 **Authors' contributions:**

1122 **LB:** Conceptualization, Methodology, Writing - Original Draft, Writing - Review &
1123 Editing, Visualization, Supervision, Project administration; **JS:** Formal analysis,
1124 Investigation, Writing - Review & Editing, Visualization; **JR:** Investigation, Writing -
1125 Review & Editing; **BG:** Investigation, Writing - Review & Editing, Project

1126 administration; **CL**: Investigation, Writing - Review & Editing; **AK**: Formal analysis,
1127 Writing - Review & Editing; **AB**: Formal analysis, Writing - Review & Editing; **TS**:
1128 Writing - Review & Editing, Supervision.

1129 **Funding:**

1130 This research did not receive any specific grant from funding agencies in the public,
1131 commercial, or not-for-profit sectors.

1132 **Availability of data and materials:**

1133 The datasets used and/or analysed during the current study are available from the
1134 corresponding author on reasonable request.

1135 **Ethics approval and consent to participate:**

1136 This study has obtained informed consent from participants, was carried out in
1137 accordance with the Declaration of Helsinki and was approved by the ethics
1138 committee of the Osteopathic Research Institute (Nr. 020-01).

1139 **Consent for publication:**

1140 Written informed consent for publication of the images was obtained from the
1141 subjects.

1142 **Competing interests:**

1143 The authors declare that they have no competing interests.